EP0964851A1

EP0964851A1 - C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion

Info

Publication number: EP0964851A1
Application number: EP98902771A
Authority: EP
Inventors: Steven K. Davidsen; Alan Scott Florjancic; George S. Sheppard; Jamie R. Giesler; Lianhong Xu; Yan Guo; Michael L. Curtin; Michael R. Michaelides; Carol K. Wada; James H. Holms
Original assignee: Abbott Laboratories
Current assignee: Abbott Laboratories
Priority date: 1997-01-07
Filing date: 1998-01-07
Publication date: 1999-12-22
Also published as: AR011061A1; AU5958298A; TW399042B; CA2277105A1; WO1998030541A1; CO4920222A1; JP2002503216A; ZA9818B

Abstract

C-terminal compounds of formula (I) are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.

Description

OF MATRIX METALLOPROTEINASES AND TNFA C-TERMINAL KETONE HYDROXAMIC ACID INHIBITORS

SECRETION

Technical Field This invention relates to compounds having activity to inhibit matrix metalloproteinases and

TNFα secretion, to pharmaceutical compositions comprising these compounds, and to a medical method of treatment. More particularly, this invention concerns C-terminal ketone compounds which inhibit matrix metalloproteinases and TNFα secretion, pharmaceutical compositions comprising these compounds and a method of inhibiting matrix metalloproteinases and TNFα secretion.

Background of the Invention The matrix metalloproteinases (MMP's) are a class of extracellular enzymes including collagenase, stromelysin, and gelatinase which are believed to be involved in the tissue destruction which accompanies a large number of disease states varying from arthritis to cancer. Typical connective tissue cells are embedded within an extracellular matrix of high molecular weight proteins and glycoproteins. In healthy tissue, there is a continual and delicately- balanced series of processes which include cell division, matrix synthesis, and matrix degradation. In certain pathological conditions, an imbalance of these three processes can lead to improper tissue restructuring. For example, in arthritis, joint mobility can be lost when there is improper remodelling of load-bearing joint cartilage. In the case of cancer, lack of coordination of cell division and the two processes of matrix synthesis and degradation can lead to conversion of transformed cells to invasive phenotypes in which increased matrix turnover permits tumor cells to penetrate basement membranes surrounding capillaries leading to subsequent metastasis.

There has been hightened interest in discovering therapeutic agents which bind to and inhibit MMP's. The discovery of new therapeutic agents possessing this activity will lead to new drugs having a novel mechanism of action for combatting disease states involving tissue degenerative processes including, for example, rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodonritis, gingivitis, corneal, epidermal or gastric ulceration, and tumor growth and metastasis or invasion. Tumor Necrosis Factor α (TNFα) is a potent proinflammatory mediator which has been implicated in inflammatory conditions including arthritis, asthma, septic shock, non-insulin dependent diabetes mellitus and inflammatory bowel disease. TNFα is originally expressed as a membrane- bound protein of about 26 kD, which is proteolytically cleaved to release a soluble 17 kD fragment (TNFα processing) which combines with two other secreted TNFα molecules to form a circulating 51 kD homotrimer. Recently, several MMP inhibitors were found to inhibit TNFα processing (see Mohler, et al., Nature, 1994, 370, 218; Gearing, et al., Nature, 1994, 370, 555; and McGeehan, et al., Nature, 1994, 370, 558), leading to the hypothesis that TNFα processing is caused by an as yet uncharacterized metalloproteinase residing in the plasma membrane of cells producing Tj α. Inhibitors of this metalloproteinase would therefore be useful as therapeutics to treat disease states involving TNFα secretion.

Transforming growth factor alpha (TGFα) is a potent mitogen which ellicites its biological activity by binding to cell surface receptors, in particular epidermal growth factor (EGF) receptor. It is known to promote angiogenesis and to stimulate epithelial cell migration and therefore has been implicated in a number of malignant disorders such as breast cancer and ovarian carcinoma. TGFα is produced by proteolytic cleavage of a 160 amino acid membrane bound precursor.

Several cleavage sites have been identified including Ala38-Val39, similar to the cleavage site of proTNFα (Ala-76- Val77). This common cleavage site suggests that inhibitors of TNFα processing may also block the cleavage of proTGFα and therefore would be therapeutically useful in diseases mediated by TGFα.

Summary of the Invention The present invention provides a novel class of C-terminal ketone inhibitors of matrix metalloproteinases and/or TNFα secretion. In its principle embodiment, the present invention provides a macrocyclic compound of formula I

or a pharmaceutically acceptable salt, ester or prodrug thereof wherein

W is NHOH or -OH.

R¹ and R⁴ are independently selected at each occurrence from hydrogen or alkyl of one to four carbon atoms. V is O or NOR¹.

R² is selected from the group consisting of

(a) hydrogen,

(b) hydroxy,

(c) alkoxy of one to six carbon atoms, d) alkyl of one to six carbon atoms, e) alkyl of one to six carbon atoms substituted with

1) halogen,

2) hydroxy,

3) alkoxy of one to six carbon atoms,

4) cycloalkyl of three to eight carbon atoms,

5) alkanoyloxy wherein the alkyl portion is of one to four carbon atoms,

6) pyridyl,

7) pyridyl substituted with alkyl of one to four carbon atoms,

8) phenoxy wherein the phenyl ring is unsubstituted or substitued with 1, 2 or 3 substituents independently selected from (8a) alkyl of one to four carbon atoms, (8b)hydroxy, (8c) alkoxy of one to four carbon atoms, (8d) halogen, (8e) haloalkyl of one to four carbon atoms, (8f) cyano, (8g) cyanoalkyl, (8h) -CO2R⁷ wherein R⁷ is hydrogen or alkyl of one to four carbon atoms, (8i) - CONR7R⁸ wherein R⁷ is defined above and R⁸ is selected from hydrogen, alkyl of one to four carbon atoms, alkanoyl of one to four carbon atoms, phenyl, and phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, - CONR⁹R¹⁰ wherein R⁹ and R¹⁰ are independently selected from hydrogen and alkyl of one to four carbon atoms, and -CO2R⁹,

(10) -S O^ ¹¹ wherein n is 0, 1 or 2 and R¹¹ is selected from (10a) alkyl of one to six carbon atoms, (10b) phenyl, (10c) phenyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷, -CONR⁷R⁸, (lOd) thienyl, (10e) thienyl substituted with alkyl of one to four carbon atoms, (lOf) phenylalkyl wherein the alkyl portion is of one to four carbon atoms, (lOg) phenylalkyl wherein the alkyl portion is of one to four carbon atoms, and the phenyl ring is substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷, and -CONR⁷R⁸, (10h) thienylalkyl wherein the alkyl portion is of one to four carbon atoms, and (lOi) thienylalkyl wherein the alkyl portion is of one to four carbon atoms and the thienyl ring is substituted with alkyl of one to four carbon atoms, and

(11) -NR¹²R¹³ wherein R¹² is hydrogen or alkyl of one to four carbon atoms and R¹³ is selected from (1 la) hydrogen, (l ib) alkyl of one to four carbon atoms, (1 lc) -CO2R¹⁴ wherein R¹⁴ is independently selected at each occurrence from (i) alkyl of one to four carbon atoms, (ii) haloalkyl of one to four carbon atoms, (iii) phenyl, (iv) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, nitro, cyano, cyanoalkyl, -SO2NH2, - CO2R⁷, and -COJNR⁷R⁸, (v) phenylalkyl wherein the alkylene portion is of one to four carbon 5 atoms, (vi) phenylalkyl wherein the alkylene portion is of one to four carbon atoms, and the phenyl ring is substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -SO2NH2, -CO2R⁷, and -CONR⁷R⁸, (vii) heteroarylalkyl wherein the alkylene portion is of one to four carbon atoms, and the heteroaryl group is selected from furyl, pyridyl, 10 thienyl, benzimidazolyl, imidazolyl, thiazolyl, and benzothiazolyl wherein the heteroaryl group is unsubstituted or substituted with alkyl of one to four carbon atoms, and (l id) -SO2R¹⁴, or R¹² and R¹³, together with the N atoms to which they are attached define a heterocycle selected from morpholinyl, thiomorpholinyl, thiomorpholinyl sulfone, pyrrolidinyl, piperazinyl, piperidinyl, succinimidyl, maleimidyl, glutarimidyl, phthalimidyl, naphthalimidyl,

^H>°-» IA N — ^H-^c-u I N — "^>C-Λ I N — A I N —

I C W O «c-^N- O ^ "3^ (0 ^H'^c "³° < O

(f) alkenyl of two to six carbon atoms,

(g) alkenyl of two to six carbon atoms substituted with 0 (1) halogen,

(2) hydroxy,

(3) alkoxy of one to six carbon atoms,

(4) cycloalkyl of three to eight carbon atoms,

(5) alkanoyloxy wherein the alkyl portion is of one to four carbon atoms, 5 (6) pyridyl,

(7) pyridyl substituted with alkyl of one to four carbon atoms,

(8) phenoxy wherein the phenyl ring is unsubstituted or substitued with 1, 2 or 3 substituents independently selected from (8a) alkyl of one to four carbon atoms, (8b) hydroxy, (8c) alkoxy of one to four carbon atoms, (8d) halogen, (8e) haloalkyl of one to four carbon atoms, (8f) cyano, 0 (8g) cyanoalkyl, (8h) -CO₂R⁷, (8i) -CONR⁷R⁸, (8j) phenyl, and (8k) phenyl substituted with 1 , 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO₂R⁹, and -CONR^RlO,

(10) -S(O)_nR^π and (1 1) -NR12R13;

R³ is selected from the group consisting of

(a) alkyl of one to ten carbon atoms,

(b) alkenyl of two to ten carbon atoms,

(c) cycloalkyl of three to eight carbon atoms, (d) (cycloalkyl)alkyl wherein the cycloalkyl portion is of three to eight carbon atoms, and the alkylene portion is of one to six carbon atoms,

(e) cycloalkylene of five to eight carbon atoms,

(f) (cycloalkylene)alkyl wherein the cycloalkylene portion is of three to eight carbon atoms, and the alklene portion is of one to six carbon atoms, (g) phenyl wherein the phenyl ring is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from (g 1 ) alkyl of one to four carbon atoms, (g2) alkoxy of one to four carbon atoms, (g3) halogen, (g4) haloalkyl of one to four carbon atoms, (g5) cyano, (g6) cyanoalkyl, (g7) -CO2R⁷, (g8) -CO2NR⁷R⁸, (g9), alkoxyalkyloxy and (glO) phenyl substituted with 1 , 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁹, and -CONR RlO,

(h) phenylalkyl wherein the alkylene portion is of one to six carbon atoms, and the phenyl ring is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from (hi) alkyl of one to four carbon atoms, (h2) alkoxy of one to four carbon atoms, (h3) halogen, (h4) haloalkyl of one to four carbon atoms, (h5) cyano, (h6) cyanoalkyl, (h7) -CO2R⁷, (h8) -CO2NR⁷R⁸, (h9) phenyl, and (hlO) phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷ and -CO2NR⁷R⁸, (i) -(CH2)_m-T-(CH2)n-R¹⁵ wherein m and n are independently 0, 1, 2, 3 or 4, T is O or S, and R¹⁵ is selected from the group consisting of (il) alkyl of one to four carbon atoms, (i2) phenyl, and (i3) phenyl substituted with 1, 2, or 3 substituents selected from (i) alkyl of one to four carbon atoms, (ii) hydroxy, (iii) alkoxy of one to four carbon atoms, (iv) halogen, (v) haloalkyl of one to four carbon atoms, (vi) cyano, (vii) cyanoalkyl, (viii) -CO2R⁷, (ix) - CONR⁷R⁸, (x) phenyl, and (xi) phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷, and -CONR⁷R⁸. and (j) fluorenylalkyl wherein the alkylene portion is of one to four carbon atoms, and R⁵ is selected from the group consisting of (a) alkyl of one to six carbon atoms,

(b) alkyl of one to six carbon atoms substituted with (bl) cycloalkyl of three to eight carbon atoms, (b2) hydroxy, (b3) alkoxy, (b4) -SR⁷, (b5) -NR R⁸, (b6) -CO R⁷, (bl) -CONR⁷R⁸, (b8) guanidyl, (b9) phenyl, (blO) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, nitro, cyano, cyanoalkyl, carboxyalkyloxy, -S(O)_nR¹⁶ wherein n is 0, 1 or 2 and R¹⁶ is alkyl of one to four carbon atoms, -SO2NH2, -CO2R⁷, and - CONR⁷R⁸, and (bl 1) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, (blO) naphthyl, (bl 1) naphthyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, (bl2) indolyl, (bl3) indolyl substituted with alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, -SO2R¹³, -SO2NH2, -CO2R⁷ and - CONR⁷R⁸, (bl4) pyridyl, (bl5) pyridyl substituted with alkyl of one to four carbon atoms, (bl6) pyrazolyl, (bl7) pyrazolyl substituted with alkyl of one to four carbon atoms, (bl8) 5-oxadiazolyl, (bl9) imidazolyl, and (b-20) imidazolyl substituted with alkyl of one to four carbon atoms,

(c) phenyl and

(d) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms.

R⁶ is selected from the group consisting of

(a) alkyl of one to six carbon atoms,

(b) alkyl of one to six carbon atoms substituted with hydroxy, alkoxy, halogen, and -CO2R¹⁷ wherein R¹⁷ is selected from hydrogen, alkyl of one to four carbon atoms and alkenyl of two to four carbon atoms,

(c) phenyl,

(d) phenyl substituted with 1, 2, or 3 substituents selected from (dl) alkyl of one to four carbon atoms, (d2) halogen, (d3) hydroxy, (d4) hydroxyalkyl of one to four carbon atoms, (d5) haloalkyl of one to four carbon atoms, (d6) alkoxy of one to four carbon atoms, (d7) cyano, (d8) -NR R⁸, (d9) -SO₂NR⁷R⁸, (dlO) -SO₂R¹⁶, (dl 1) -CH₂NRl Rl⁹, wherein Rl⁸ and R¹⁹ are independently selected at each occurrence from hydrogen and alkyl of one to four carbon atoms, or R¹⁸ and R¹⁹ together with the N atom to which they are attached define a a 5-or 6-membered heterocyclic ring selected from morpholinyl, thiomorpholinyl, thiompholinyl sulfone, pyrrolidinyl, piperazinyl, 3-ketopiperazinyl and piperidinyl, (dl2) -CONR⁷R⁸, (dl3) -CO2R⁷, and (dl4) phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, (e) 1,3-benzodioxole,

(f) indolyl,

(g) indolyl substituted with (gl) alkyl of one to four carbon atoms, (g2) halogen, (g3) haloalkyl of one to four carbon atoms, (g4) alkoxy of one to four carbon atoms, (g5) -SO2NR⁷R⁸, (g6) -CO2R⁷, (g7) alkylsulfonyl of one to four carbon atoms, and (g8) phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms,

(h) pyrrolyl,

(i) pyrrolyl substituted with alkyl of one to four carbon atom

(j) imidazolyl, (k) imidazolyl substituted with alkyl of one to four carbon atoms,

(1) benzimidazolyl,

(m) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (f)-(m) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms, -

CONR7R⁸, -SO₂NR⁷R⁸ and -SO₂R¹⁴,

(n) pyridyl,

(o) pyridyl substituted with alkyl of one to four carbon atoms,

(p) thienyl, (q) thienyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms,

(r) thiazolyl,

(s) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (t) oxazolyl,

(u) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms,

(v) furyl,

(w) furyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms,

(x) benzofuryl, (y) benzofuryl substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, (z) benzothiazolyl, and

(aa) benzothiazolyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms.

In another aspect, the present invention provides pharmaceutical compositions which comprise a therapeutically effective amount of compound of formula I in combination with a pharmaceutically acceptable carrier.

In yet another aspect, the present invention provides a method of inhibiting matrix metalloproteinases and/or TNFα secretion in a host mammal in need of such treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I.

Detailed Description As used throughout this specification and the appended claims, the following terms have the meanings specified.

The term alkyl refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom. Alkyl groups are exemplified by methyl, ethyl, n- and wo-propyl, n-, sec-, iso- and tert-butyl, and the like. The term alkylsulfonyl represents an alkyl group, as defined above, attached to the parent molecular group through a SO2 group.

The term "alkanoyl" represents an alkyl group, as defined above, attached to the parent molecular moiety through a carbonyl group. Alkanoyl groups are exemplified by formyl, acetyl, propionyl, butanoyl and the like. The terms alkoxy and alkoxyl denote an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. Representative alkoxy groups include methoxy, ethoxy, propoxy, butoxy, and the like.

The term "alkoxycarbonyl" represents an ester group; i.e. an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like.

The term alkenyl as used herein refer to monovalent straight or branched chain groups of 2 to 6 carbon atoms containing a carbon-carbon double bond, derived from an alkene by the removal of one hydrogen atom and include, but are not limited to groups such as ethenyl, 1-propenyl, 2- propenyl, 2-methyl- 1-propenyl, 1-butenyl, 2-butenyl and the like. The term alkylene denotes a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon containing by the removal of two hydrogen atoms, for example -CH2-, -CH2CH2-, -CH(CH3)CH2- and the like. The term alkenylene denotes a divalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. Examples of alkenylene include - CH=CH-, -CH₂CH=CH-, -C(CH₃)=CH-, -CH₂CH=CHCH₂-, and the like.

The terms alkynylene refers to a divalent group derived by the removal of two hydrogen atoms from a straight or branched chain acyclic hydrocarbon group containing at least one carbon- carbon triple bond. Examples of alkynylene include -CH≡CH-, -CH≡C-CH2-, -CH≡CH- CH(CH₃)- and the like.

The term cycloalkyl as used herein refer to a monovalent saturated cyclic hydrocarbon group. Representative cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2. ljheptane and the like.

Cycloalkylene denotes a divalent radical derived from a cycloalkane by the removal of two hydrogen atoms.

The terms "(cycloalkyl)alkyl" and "(cycloalkenylene)alkyl" refer, respectively, to a cycloalkyl group or cycloalkenylene group as defined above attached to the parent molecular moiety through an alkylene group.

The term cyanoalkyl denotes an alkyl group, as defined above, substituted by a cyano group and includes, for example, cyanomethyl, cyanoethyl, cyanopropyl and the like.

The term haloalkyl denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.

The term "hydroxyalkyl" represents an alkyl group, as defined above, substituted by one to three hydroxyl groups with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group.

The term "phenoxy" refers to a phenyl group attached to the parent molecular moiety through an oxygen atom.

By pharmaceutically acceptable salt is meant those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art . For example, S. M Berge, et al. describe pharmaceutically acceptable salts in detail in J.

Pharmaceutical Sciences, 1977, 66:1 - 19 . The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

As used herein, the term "pharmaceutically acceptable ester" refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable ahphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters includes formates, acetates, propionates, butyates, acrylates and ethylsuccinates.

The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

Asymmetric centers may exist in the compounds of the present invention. The present invention contemplates the various stereoisomers and mixtures thereof. Individual stereoisomers of compounds of the present invention are made by synthesis from starting materials containing the chiral centers or by preparation of mixtures of enantiomeric products follwed by separation as, for example, by conversion to a mixture of diastereomers followed by separation by recrystallization or chromatographic techniques, or by direct separation of the optical enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods detailed below and resolved by techniques well known in the organic chemical arts. Preferred Embodiments Preferred compounds of the present invention have formula I wherein R^ is defined therein; R¹ and R⁴ are hydrogen; R² is selected from the group consisting of

(a) hydrogen,

(b) hydroxy,

(c) alkoxy of one to six carbon atoms,

(d) alkyl of one to six carbon atoms,

(e) alkyl of one to six carbon atoms substituted with

(2) -S(O)_nR^π wherein n is 0, 1 or 2 and R¹¹ is selected from (2a) phenyl, (2b) phenyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷, and -CONR⁷R⁸, (2c) thienyl and (2d) thienyl substituted with alkyl of one to four carbon atoms and (3) -NR¹²R¹³ wherein R¹² and R¹³ are independently selected from hydrogen and alkyl of one to four carbon with the N atoms to which they are attached define a

heterocycle

(f) alkenyl of two to six carbon atoms; R³ is selected from the group consisting of

(a) alkyl of one to ten carbon atoms, (b) cycloalkyl of three to eight carbon atoms, and

(c) phenylalkyl wherein the alkylene portion is of one to six carbon atoms, and the phenyl ring is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from (cl) alkyl of one to four carbon atoms, (c2) alkoxy of one to four carbon atoms, (c3) halogen, (c4) haloalkyl of one to four carbon atoms, (c5) cyano, (c6) cyanoalkyl, (c7) -CO2R⁷, (c8) -CO2NR⁷R⁸, (c9) phenyl, and (clO) phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷ and -CO2NR⁷R⁸; and R⁵ is selected from

(a) alkyl of one to six carbon atoms,

(b) alkyl of one to six carbon atoms substituted with (bl) cycloalkyl of three to eight carbon atoms, (b2) -CO R⁷, (b3) -SR⁷, (b4) phenyl, and (b5) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, nitrό, cyano, cyanoalkyl, -S(O)_nR¹⁶ wherein n is 0, 1 or 2 and R¹⁶ is alkyl of one to four carbon atoms, - SO2NH2, -CO₂R⁷, and -CONR⁷R⁸.

More preferred compounds have the structure immediately above wherein W is -NHOH and V is O. Still more preferred compounds have the structure immediately above wherein R² is selected from the group consisting of hydrogen, hydroxy and alkenyl of two to six carbon atoms; R³ is selected from the group consisting of isobutyl, cyclohexyl, 3-phenylpropyl, 3-(4- tolyl)propyl and biphenyloxy; R⁵ is selected from the group consisting of alkyl of one to six carbon atoms, and alkyl of one to six carbon atoms substituted with cycloalkyl of three to eight carbon atoms, carboxy, phenyl, and hydroxyphenyl; and R⁶ is selected from

(a) alkyl of one to six carbon atoms,

(b) alkyl of one to six carbon atoms substituted with -CO2R¹⁷,

(c) phenyl,

(d) phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, -NR⁷R⁸, cyano, -SO2NR⁷R⁸, -SO2R¹⁶, - CH₂NR¹⁸R¹⁹, -CONR⁷R⁸ and -CO₂R⁷,

(e) indolyl,

(f) indolyl substituted with alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms,

(g) pyrrolyl,

(h) pyrrolyl substituted with alkyl of one to four carbon atoms, (i) benzimidazolyl,

(j) benzimidazolyl substituted with 1 , 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (e)-(j) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms, - CONR⁷R⁸ and -SO₂NR⁷R⁸,

(k) thienyl,

(1) thienyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms,

(m) thiazolyl, (n) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (0) oxazolyl and

(p) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms.

Still yet more preferred compounds have the structure immediately above wherein R⁶ is selected from the group consisting of

(a) phenyl,

(b) phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, -NR⁷R⁸, cyano, -SO2NR⁷R⁸, -SO2R¹⁶, - CH₂NRl R¹⁹, -CONR⁷R⁸ and -CO₂R⁷,

(c) indolyl,

(d) indolyl substituted with alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and phenyl, wherein the phenyl ring may be substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms,

(e) pyrrolyl,

(f) pyrrolyl substituted with alkyl of one to four carbon atoms,

(g) benzimidazolyl,

(h) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (c)-(h) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms, - COjNRiSRlθ and -SO₂NR¹⁵R¹⁶,

(i) thienyl, (j) thienyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (k) thiazolyl,

(1) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (m) oxazolyl and

(n) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms.

The most preferred compounds of this invention have the structure immediately above wherein R⁶ is selected from the group consisting of phenyl and phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, -NR⁷R⁸, cyano, -SO NR⁷R⁸, -SO₂R¹⁶, -CH₂NRl⁸Rl⁹, -CONR⁷R⁸, -CO₂R⁷, and phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms.

Determination of Stromelysin Inhibition The efficacy of the compounds of this invention as matrix metalloproteinase inhibitors was determined by measuring the inhibition of stromelysin. The inhibition of stromelysin by the compounds of this invention was determined as follows: Recombinant truncated stromelysin (human sequence) produced in E. coli was prepared by expression and purification of the protein as described by Ye et al., Biochemistry , 1992, 31, 11231-11235. The enzyme was assayed by its cleavage of the thiopeptide ester substrate Ac-Pro-Leu-Gly-[2-mercapto-4-methyl-pentanoyl]- Leu-Gly-OEt described by Weingarten and Feder, Anal. Biochem. , 1985, 147, 437-440 (1985), as a substrate of vertebrate collagenase. The reported conditions were modified to allow assays to be carried out in a microtiter plate. Upon hydrolysis of the thioester bond, the released thiol group reacts rapidly with 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB), producing a yellow color which is measured by a microtiter plate reader set at 405 nm. The rates of cleavage of the substrate by stromelysin in the presence or absence of inhibitors are measured in a 30 min assay at ambient temperature. Solutions of the compounds in DMSO are prepared, and these are diluted at various concentrations into the assay buffer (50 mM MES/NaOH pH 6.5 with 10 mM CaCl2 and 0.2% Pluronic F-68), which is also used for dilution of the enzyme and substrate. The potency of the compounds [IC50] are calculated from the inhibition/inhibitor concentration data. The compounds of this invention inhibit stromelysin as shown by the data for representative examples in Table 1.

Table 1

Inhibitory Potencies against Stromelysin of Representative Compounds

Pharmaceutical Compositions

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally , intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof. Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology. Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Generally dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

Preparation of Compounds of this Invention The compounds of this invention may be prepared by a variety of synthetic routes. Representative procedures are outlined in the following Schemes 1-3.

Abbreviations which have been used in the descriptions of the schemes and the examples that follow are: THF for tetrahydrofuran; DMF for NN-dimethylformamide; ETOAc for ethyl acetate; Et2θ for diethyl ether, IPA for isopropanol; ETOH for ethanol; MeOH for methanol; AcOH for acetic acid; HOBT for 1-hydroxybenzotriazole hydrdate; EDC for l-(3-dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloride; NMM for N-methylmorpholine; Bu₃P for tributylphosphine; ADDP for l,l'-(azodicarbonyl)dipiperidine; and DMPU for l,3-dimethyl-3,4,5,6-tetrahydro- 2( lH)-pyrimidinone.

The preparation of representative compounds of the invention, wherein R!-R⁶ and W are defined above, is outlined in Scheme 1. Coupling of succinic acid derivative 1 with keto amine 2 in the presence of an tertiary amine base, hydro xybenzotriazole (HOBt), and a suitable coupling agent such as l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI»HC1) gives 3. Conversion of 3 to the corresponding carboxylic acid 4 is accomplished by acidic removal of the tert-butyl ester using, for example, trifluoroacetic acid or hydrogen chloride in dioxane. Treatment of this acid with hydroxylamine or a hydroxylamine equivalent such as O-tert- butyldimethylsUylhydroxylarnine in the presence of a suitable coupling agent such as EDCI»HC1 gives hydroxamate 5. OBenzylhydroxylamine can also be employed in this coupling reaction. The resultingO-benzylhydroxamate can then be treated with hydrogen and a palladium catalyst such as 10% palladium on carbon to produce hydroxamate 5.

Scheme 1

Preparation of keto amine 2 is accomplished as shown in Scheme 2. Conversion of the protected amino acid 6 to the methyl ester or N,O-dimethylamide is accomplished by known methods. Reaction of 7 with R⁶MgX wherein X is Br, Cl or I, or R⁶Li generates ketone 8. Acidic removal of the tert-butyl protecting groups gives amino ketone 2. Alternatively, 6 can be treated with a carbon anion such as phenyllithium which gives 8 directly. Scheme 2

a

The preparation of the succinic acid derivative 1 is shown in Scheme 3. Treatment of oxazolidinone 2 with a suitable base such as lithium diisopropylamide followed by addition of tert- butyl bromoacetate and basic hydrolysis gives carboxylic acid \Q. This acid is treated with at least two equivalents of a strong base such as lithium diisopropylamide followed by an alkylating agent R²X wherein X is Br, Cl or I. The resulting dialkyl succinate JJ. is again treated with a strong base such as lithium diisopropylamide followed by either methanol (R¹ = H) or an alkyl halide (R¹ = alkyl) such as methyl iodide to give substituted succinate 1.

Scheme 3

10 11 1

The foregoing may be better understood by reference to the following examples which are presented for illustration and are not intended to limit the scope of the invention as defined in the appended claims. Preparation of Succinate Ester 1

A mixture of 4-methylvaleric acid (50.7 g, 0.43 mmol) and thionyl chloride (40 mL, 65.2 g, 0.54 mole) was stirred at ambient temperature for 18 hours. The mixture was heated to distill the excess reagent through a 10 cm Vigreux column. The acid chloride was then distilled to give i (48.43 g, 84 %), bp 135-138 °C.

To a -78 °C solution of 4S-benzyl-2-oxazolidinone (62.2 g, 0.35 mole) in THF (600 mL) was addedn-butyllithium (140 mL, 2.5 M in hexane) over 1 hour. After 30 minutes i (0.359 mole) was added over 10 minutes during which time the temperature rose to -60 °C. After 1 hour the bath was removed and the reaction mixture was warmed to 0 °C. The reaction was quenched with saturated ammonium chloride, the mixture was allowed to settle, and the supernatant was decanted and concentrated. The combined residues were partitioned between water and ethyl acetate. The organic layer was washed with water, IM sodium bicarbonate, water and brine, dried over sodium sulfate, filtered and concentrated. The residue was distilled discarding a small forerun to give n (92.9 g, 96%), bp 154-156 °C / 0.15 mm.

To a mechanically-stirred -78 °C solution of ϋ (92.9 g, 0.337 mole) in THF (IL) was added sodium bis(trimethylsilyl) amide (375 mL, IM in THF) over 40 minutes. The reaction mixture was stirred for 30 minutes and t-butyl bromoacetate (55 mL, 72.6 g, 0.372 mole)was added over 30 minutes. The reaction mixture was stirred for 30 minutes and then the cold bath was removed and the mixture was warmed to 0 °C. The reaction was quenched with saturated ammonium chloride. After mixing well, the mixture was allowed to settle and the supernatant was decanted, concentrated, and recombined with the residue. This mixture was partitioned between water and ethyl acetate. The organic layer was washed with water, 1 M sodium bicarbonate, water and brine, dried over sodium sulfate and concentrated by distillation to about 250 mL. After dilution with 750 mL hexane and cooling in an ice bath the resulting crystals were collected and washed with hexane to provide in (104.6 g) mp 101-102 °C. The mother liquors were concentrated and the residue was purified by chromatography on silica gel (5 - 10% ethyl acetate - hexane) and the product fraction crystallized to yield 7.6 g more for a total of 112.2 g (85 %).

To a 0 °C solution of Hi (112.2 g, 0.288 mole) in THF (1.2 L) was added water (100 mL) and 30 % hydrogen peroxide (110 mL, 36.6 g, 1.08 mole). A solution of lithium hydroxide monohydrate (17.8 g, 0.424 mole) in water (400 mL) was added in portions over 25 minutes and the resulting solution was stirred for 1 hour. The mixture was concentrated under a slow nitrogen stream to about 800 mL. After seeding with the chiral oxazolidinone the mixture was chilled and filtered removing a portion of the auxiliary which was washed well with water. The filtrate was extracted with dichloromethane (3x) to remove the balance of the chiral oxazolidinone. The combined organic extracts were washed with aqueous 0.5 N sodium hydroxide. The base layers were acidified with IM sulfuric acid to pH 3 and extracted with ethyl acetate. After washing with water and brine, drying over sodium sulfate, and evaporation of solvents the residue amounted to 64.9 g (98%) of R-2-( -butyl)-succinic acid-4-t-butyl ester.

Step 5

To a -78 °C solution of hthium diisopropylamide, prepared by the addition of n- butyllithium (11.4 ml, 28.4 mmol, 2.5M in hexanes) to a solution of diisopropylamine (3.7 ml, 28.4 mmol) in 60 ml THF at -78 °C, was added a solution of |y (2.7 g, 11.8 mmol) in THF (20 mL) at -78 °C by cannula in a stream. The resulting clear, yellow solution was stirred at -78 °C for lhour and then butenyl iodide (2.58 g, 14.2 mmol) was added by syringe. This mixture was allowed to warm to ambient temperature and stir overnight. The reaction mixture was poured into 1:1 ether- water and the separated aqueous layer was extracted with ether (2x). The combined organic layers were washed with aq IM NaHSO and brine, dried with MgSO₄, filtered and concentrated. Flash chromatography (2%-5% isopropanol-hexane) gave epimeric succinates y (2.30 g, >9:1 syn/anti) as a clear liquid.

Step 6

To a -78 °C solution of hthium diisopropylamide, prepared by the addition of n- butyllithium (7.8 ml, 19.5 mmol, 2.5M in hexanes) to a solution of diisopropylamine (2.6 ml, 19.5 mmol) in 30 ml THF at -78 °C, was added a solution of epimeric isobutyl succinate y (2.3 g, 8.1 mmol) in THF (10 mL) at -78 °C by cannula in a stream. The resulting clear, yellow solution was stirred at -78 °C for 1 hour, warmed to 0 °C and recooled to -78 °C. Methanol (1 ml) was added and the solution was warmed to 0 °C. The reaction mixture was poured into 1: 1 ether- water and the separated aqueous layer was extracted with ether (2x). The combined organic layers were washed with aq IM NaHSO and brine, dried with MgSO₄, filtered and concentrated to give an epimeric mixture (2:1 anti/syn) of succinates y which could be separated by flash chromatography (10-50% ethyl acetate-hexanes). Preparation of Succinate Ester 2

The desired compound was prepared according to the method used to prepare succinate ester 1, except substituting allyl bromide for 4-bromo-l-butene.

Preparation of Succinate Ester 3

The desired compound was prepared according to the method used to prepare succinate ester 1, except substituting 5-bromo-l-pentene for 4-bromo-l-butene.

Preparation of Succinate Ester 4

mixture of isomers

A mixture under nitrogen of 4-bromotoluene (36.9 mL, 51.3 g, 0.3 mole), 4-pentenoic acid (30.6 mL, 30.0 g, 0.3 mole), acetonitrile (500 mL), triethylamine (126 mL, 91.5 g, 0.90 mole), palladium acetate (1.35 g, 6 mmole) and tri-(ø-tolyl)phosphine (4.65 g, 15 mmole) was heated slowly to a gentle reflux. (A mild exotherm was observed as reflux begins.) After 18 hours at reflux, the mixture was cooled in an ice bath and the solid was removed by filtration and rinsed well with ethyl acetate. The filtrate was concentrated to a small volume and the residue was partitioned between aqueous 1 M sodium carbonate and ether. The aqueous phase was extracted with ether. The combined ether layers were extracted with aqueous 1 M sodium carbonate. The basic solution was treated with charcoal and filtered. The filtrate was acidified with 3 M hydrochloric acid. After cooling in an ice bath, the soft solid was filtered, washed with ice water, and dried over sodium hydroxide to give yn (45 g) as a mixture of isomers which was used without further purification.

The mixtureof isomers yϋ was hydrogenated in 600 mL THF over 9 g of 10% palladium on carbon at 4 atmospheres of hydrogen for 18 hours. After filtration and concentration of the solution, the residue was crystalhzed from hexane to yield 5-(4-tolyl)pentanoic acid (viii, 33 g, mp 77-78 °C).

A mixture of 30b (11.02 g, 57 mmole) and 12 mL thionyl chloride was stirred at 24 °C for 18 hours and then heated to distill most of the excess thionyl chloride. Short path distillation gave 11.74 g (97 %) of 5-(4-tolyl)pentanoyl chloride (30c, bp ~ 110 °C at 0.35 mm).

To a -78 °C solution of 4S-benzyl-2-oxazolidinone (10.36 g, 58 mmole) in THF (150 mL) was added n-butyllithium (23.5 mL 2.5 M) over 25 minutes. After 30 minutes, 3_0_£ (55.7 mmole) was added quickly, during which time the reaction temperature rose to -45 °C. The reaction mixture was warmed to 0 °C and the reaction was quenched with saturated aqueous ammonium chloride. The mixture was allowed to settle and the supernatant was decanted and concentrated. The residue was partitioned between water and ethyl acetate. The organic layer was washed with water, aqueous IM sodium bicarbonate, water and brine. After drying over sodium sulfate the solution was concentrated and the residue was chromatographed (10-20 % ethyl acetate-hexane) to give 30d (17.83 g, 89%).

The desired compound was prepared using Step 4 of the preparation of succinate ester 1, except substituting x for ni.

Preparation of Succinate Ester 5

The desired compound was prepared using steps 5 and 6 of the preparation of succinate ester 1 , except substituting succinate ester 4 for jy.

Preparation of Succinate Ester 6

To a cold (0°) solution of succinate ester 2 (0.79g, 3mmol) in 10 mL methylene chloride was added pentaflurophenol (0.65g, 3.5mmol) and EDCI (0.69g, 3.5mmol). The resulting solution was stirred for 16 hours while warming to ambient temperature. The reaction mixture was quenched with 2N Na2CO₃. The organic layer was washed with 2N HCl and brine, dried (sodium sulfate) and concentrated to give succinate ester .8 (0.8 g) as a crude yellow oil, which was used without further purification.

Preparation of succinate Ester 7

The desired compound was prepared using steps 1-4 of the preparation of succinate ester 1, except substituting 4-pentenoic acid for 4-methyl valeric acid in step 1.

Preparation of succinate Ester 8

The desired compound was prepared from the succinate ester 7 using the Suzuki coupling conditions described in Example 4 IB.

Preparation of succinate Ester 9

The desired compound was prepared from succinate ester 8, using step 5 of the preparation of succinate ester 1, except substituting allyl iodide for butenyl iodide.

Preparation of succinate Ester 10

The desired compound was prepared using steps 1 -4 of the preparation of succinate ester 1, except substituting 6-benzyloxyhexanoic acid for 4-methyl valeric acid in step 1.

Preparation of succinate ester 11

Step 1

xi xii

Prepared as described for 4-(trimethylsilyl)-3-butyn-l-ol in Organic Syntheses 1993, Volume Vm, p. 609.

IH NMR (300 MHz, CDC1 ) δ 3.68 (t, 2H), 2.27 (t, 2H), 1.68-1.62 (m, 4H), 0.14 (s, 9H).

Step 2

xϋi xiv

Prepared as described in Tetrahedron Letters 1979, p. 399. ^l NMR (300 MHz, CDC1₃) δ 2.50 (t, 2H), 2.32 (t, 2H), 1.84 (t, 2H), 0.14 (s, 9H).

The desired compound was prepared using steps 1 -4 of the preparation of succinate ester 1, except substituting 6-(trimethylsilyl)-5-hexynoic acid for 4-methyl valeric acid in step 1.

^!H NMR (300 MHz, CDC1 ) δ 3.03-2.94 (m, IH), 2.64 (dd, IH), 2.47 (dd, IH), 2.31 (td, 2H),

2.00 (t, IH), 1.99-1.90 (m, IH), 1.81-1.69 (m, IH), 1.45 (s, 9H).

MS (DCI/NH₃) m/e 227 (M+l)⁺.

To a 0° C solution of L-phenylalanine (25 g, 151 mmol) in aqueous IN NaOH (175 mL) was added methyl chloroformate (15 g, 159 mmol) via syringe over several minutes. The pH was adjusted to 14 with IN NaOH and the resulting clear solution was stirred for 1 hour. The basic solution was extracted with ether (3x) and the organics were discarded. The pH was adjusted to 3 with a cold phosphoric acid (~1N) and the acidic solution was extracted with methylene chloride (3x). The combined organics were washed with brine, dried (Na2SO4) and concentrated in vacua to give Ja (32g) as an extremely viscous oil which was carried on without further purification.

Example IB

To a 0 °C solution of la (4.9 g, 21 mmol) in anhydrous diethyl ether (250 mL) was added PCI5 (5.25g, 25.5mmol) over several minutes. The resulting suspension was allowed to stir for 1 hour during which time it slowly became a pale yellow solution. Solvent was removed in vacuo and the resulting acid chloride was dried under high vacuum for 1 hour. The crude acid chloride was then dissolved in methylene chloride (250 mL), cooled to 0 °C, and indole (2.9 g, 25.2 mmol) was added over 10 minutes. A1C1 (5.5g, 50mmol) was then added over a period of 5 minutes, during which time the solution became a blood-red color, and the reaction mixture was allowed to warm to ambient temperature and stir for 16 hours. The reaction mixture was poured into cold water and extracted with methylene chloride. The combined organics were washed with brine, dried (Na2SO4) and concentrated in vacuo to give 7.5g of a crude red solid. Hash chromatography (hexane-ethyl acetate, gradient elution 3:1 to 1:1) gave 2.6 g of a product lb containing ~60% of the desired acylation product which was carried on without further purification.

Example IC

To a solution of lb (2.4 g) in 3:1 MeOH/water (40 mL) was added KOH (2.1 g, 37.3 mmol). The resulting solution was heated at reflux for 18 hours, cooled and acidifed with IN phosphoric acid. The acidic aqueous layer was extracted with ethyl acetate (3x) and the organic layer discarded. The aqueous layer was made basic with aqueous 3N NaOH solution and extracted with methylene chloride (3x). The combined organics were washed with brine, dried (Na2SO4) and concentrated in vacuo to give the desired compound ic (482mg) as a racemic mixture.

Example ID

To a solution of ic (0.48 g, 1.8 mmol) in DMF was added succinate ester 6 (0.8 g, 1.8 mmol). The reaction was allowed to stir at ambient temperature for 16 hours, then was warmed to 45 °C for 3 days. The reaction mixture was diluted with ethyl acetate and the organic layer washed with IN NaOH, water (4x), dried (Na2SO4), filtered and concentrated to give 1 g of a tan foam. Flash chromatography (hexane-ethyl acetate 5:1) gave id (510 mg) as a 1:1 mixture of epimers at the Phe center. Example IE

Ester id (0.5 g, 1.0 mmol) was dissolved in cold (0°) TFA and stirred for 5 hours while warming to ambient temperature. Solvent was removed under a stream of nitrogen and the residue was azeotroped with methylene chloride and dried on high vacuum for 16 hours to give le (250 mg) as a 1 : 1 mixture of epimers at the Phe center.

Example IF

To a cold (0°) solution of ie (0.25g, 0.54mmol) in DMF was added NMM (0.08 g, 0.81 mmol, 0.09 mL), HOBT (0.08 g, 0.59 mmol) and EDCI (0.11 g, 0.59 mmol). The resulting solution was stirred for 5 minutes and tertr-butyltrimethylsilylhydroxylamine (0.09 g, 0.59 mmol) was added in one portion. The resulting solution was warmed to ambient temperature and allowed to stand for 97 hours. The reaction mixture was diluted with EtOAc, washed with water (3x) and brine, dried (Na2SO4), filtered and concentrated in vacuo . Flash chromatography (1-3% methanol-methylene chloride) gave the desired compound (80mg) as a tan solid which was a 1:1 mixture of epimers at the Phe center, mp 180-210° (dec). *H NMR (300 MHz, DMSO-d6) δ 12.02 (s, IH), 10.4 (s, IH), 8.64-8.17 (m, 3H), 8.22-8.17 (m, 2H), 7.48-7.13 (m, 7H), 5.42- 5.39 (m, 2H), 4.82-4.52 (m, 3H), 3.12-30.7 (m, 2H), 2.97-2.91 (m, 2H), 2.41-2.38 (m, 2H), 2.0-1.94 (m, 3H), 1.30-1.25 (m, 2H), 1.10-1.01 (m, 2H), 0.8-0.56 (m, 8H). MS (DCI/NH₃) m/e 476 (M+H)⁺. Anal calcd for C28H ₃N₃O : C, 70.71; H, 6.99; N, 8.83. Found: C, 70.50; H, 6.99; N, 8.60.

Separation of the diastereomers prepared in Example IF by HPLC gave the compound of Example IG. mp 190-210 °C (dec). *H NMR (300 MHz, DMSO-d6) δ 11.95 (s, IH), 10.36 (s, IH), 8.68 (s, IH), 8.51-8.46 (m, 2H), 7.48-7.46 (m, IH), 7.40-7.37 (d, 2H, J = 7.1 Hz), 7.25- 7.10 (m, 4H), 5.44-5.33 (m, 2H), 4.82-4.67 (m, 2H), 3.14-3.12 (dd, IH, J = 4.1, 9.4 Hz), 2.97-2.89 (m, IH), 2.39-2.35 (m, IH), 1.98-1.83 (m, 2H), 1.30-1.25 (m, 2H), 1.21-0.99 (m, IH), 0.85-0.77 (m, IH), 0.67-0.65 (d, 3H, J = 6.4 Hz), 0.55-0.53 (d, 3H, J = 6.8 Hz). MS (DCI NH₃) m/e 476 (M+H)+ Anal calcd for C₂8H₃₃N₃O₄«0.75 H₂O: C, 68.76; H, 7.11; N, 8.59. Found: C, 68.77; H, 6.66; N, 8.52. [α]_d = -4.19° (c, 0.31, DMF).

Example IH

The desired compound was isolated in the chromatography of Example IG. mp 170-210 °C (dec). ^lH NMR (DMSO) δ 12.03 (s, IH), 10.39 (s, IH), 8.71 (s, IH), 8.64-8.61 (d, IH, J = 7.8 Hz), 8.55 (s, IH), 8.22-8.19 (d, IH, J = 6.4 Hz), 7.49-7.47 (d, IH, J = 6.4 Hz), 7.38-7.35 (d, 2H, J = 7.8 Hz), 7.27-7.17 (m, 5H), 5.41-5.40 (m, 2H), 4.72-4.68 (d, IH, J = 7.8 Hz), 4.56-4.50 (d, IH, J = 14.9 Hz), 3,12-3.07 (m, IH), 2.95-2.91 (m, IH), 2.42-2.41 (m, IH), 2.00-1.99 (m, IH), 1.76-1.72 (m, IH), 1.26-1.25 (m, IH), 0.80-0.72 (m, IH), 0.62-0.56 (m, 6H). MS (DCI/NH₃) m/e 476 (M+H)+. Anal calcd for C₂8H₃₃N O »5/4 H O: C, 67.52; H, 7.18; N, 8.44. Found: C, 67.54; H, 6.94; N, 8.42. [α]_d = 36.67° (c, 0.24, DMF).

To a solution of methyl carbamate 2a (63.32 g, 280 mmol) in ether (IL) was added PBr3 (10.8 mL, 110 mmol) via syringe at ambient temperature. The solution was allowed to stir overnight. The solvent was removed in vacuo and the resulting N-carboxyanhydride 2 (54.2 g, 100%) was dried on under high vacuum for 2 hours. The product was carried forward without further purification.

Example 2B

To a solution of 2b (28.35 g, 148 mmol) was added indole (139.12 g, 740 mmol) in one portion. The reaction mixture was cooled to 0 °C and AICI3 (59.22 g, 445 mmol) was added slowly via solid addition funnel. Upon complete addition of AICI3, the cold bath was removed and the solution was allowed to stir for 4 hours while warming to ambient temperature. The reaction was quenched by pouring onto 250 mL ice. The pH was adjusted to 12 by the dropwise addition of NH4OH. The aqueous layer was extracted twice with CH2CI2. The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo to a brown oil. Rash chromatography (1:2:97 to 1:3:96 NH4OH-MeOH-CH2Cl2) gave 2c (5 g, 16%) as a tan solid.

Example 2C

A solution of acid succinate ester 4 (1.107 g, 3.7 mmol) in 20 mL DMF was cooled to 0 °C. NMM (975 mg, 8.9 mmol) was added via syringe, followed by HOBT (602 mg, 4.5 mmol), EDCI (856 mg, 4.5 mmol), and 2c (1.18 g, 4.5 mmol). The solution was allowed to stir overnight while warming to ambient temperature. The reaction was quenched with water and extracted twice with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo. The resulting orange foam was chromatographed (1% MeOH-CH2Cl2) to give 2d (1.607 g, 80%).

Example 2D

The desired compound was prepared according to the method of Examples IE and F, except substituting 2d_ for id. mp 188 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 11.99 (d, IH, J = 3.0 Hz), 10.41 (d, IH, J = 1.5 Hz), 8.74 (d, IH, J = 1.8 Hz), 8.56-8.44 (m, 2H), 8.20-8.17 (m, IH), 7.49-7.16 (m, 8H), 5.74-5.58 (m, IH), 5.49-5.35 (m, IH), 4.95-4.86 (m, 2H), 3.18- 2.93 (m, 2H), 2.42-2.30 (m, IH), 2.21-2.11 (m, IH), 1.96-1.56 ( , 3H), 1.47-0.72 (m, 6H), 0.61 (dd, 6H, J = 36.4, 6.7 Hz). MS (APCI) m/e 504 (M+l). Anal calcd for C3θH37N3θ4:C, 71.54; H, 7.40; N, 8.34. Found: C, 70.72; H, 7.05; N, 7.10. [α]_d = -35°. Example 3

Example 3A

To a solution of phenylalanine (10 g, 61 mmol) in 500 mL of H2O was added K2CO3 (27.6 g, 200 mmol) and benzyl bromide (24 mL, 200 mmol). The reaction mixture was heated at reflux for 2.5 days and then was quenched with IM HCl and extracted with CH2CI2. The organic layer was washed with H2O, IM NaOH and brine. The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. Flash chromatography (20% EtOAc-hexane) gave 3a (48%).

To a solutiong of 3a (5.05 g, 1.16 x 10^"^ mol) in 2:1 dioxane/water (300 mL) was added KOH (0.65 g, 1.16 x 10^~2 mol) and the reaction mixture was stirred for 2 days. The reaction mixture was acidified with IM HCl and extracted with EtOAc. The organic layer was dried

(MgSO4), filtered, and concentrated in vacuo. Flash chromatography (40% EtOAc-hexane) gave 3b. Example 3C

To a 0 °C solution of 3c (2.0 g, 5.8 x 10^"3 mol) in 30 mL CH2CI2 was added EDCI (1.22 g, 6.36.x 10^-3 mol), N,0-dimethylhydroxylamine hydrochloride (0.62 g, 6.36 x 10^-3 mol), and NMM (0.764 mL, 6.96 x 10^"3 mol) and the reaction mixture was stirred at 0 °C for 10 minutes. The cold bath was removed and the reaction was allowed to warm to ambient temperature and stir overnight The reaction was quenched with H2O and extracted with CH2CI2. The organic layer was washed with citric acid, saturated aqueous NaHCO3, pH 7 buffer and brine. The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. Flash chromatography (20% EtOAc-hexane) gave 3c (48% yield).

Example 3D

To a 0 °C solution in THF (20 mL) of Weinreb amide 2c (588 mg, 1.5 mmol) was added ethylmagnesium bromide (1 mL, 3 mmol) via syringe. The ice bath was removed and the reaction mixuture was allowed to warm to ambient temperature and stir for 3.5 hours. The reaction was quenched with H2O and extracted with EtOAc. The organic layer was washed with brine, dried (MgSO4), filtered, and concentrated in vacuo. Flash chromatography (5% EtOAc-hexane) gave the desired product 3_d_ in 36% yield.

Example 3E

To a solution of ketone 3_d, (554 mg, 1.55 mmol) in 50 mL MeOH was added 20% Pd(OH)2/C and the reaction was stirred for 24 hours. The reaction was filtered to remove the catalyst and concentrated in vacuo to give the desired product in 3_£ 91% yield.

Example 3F

The desired compound was prepared according to the method of Examples 1D-F, except substituting 3e for . mp 145 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 10.36 (d, IH, J = 1.7 Hz), 8.69 (d, IH, J = 1.7 Hz), 8.20 (d, IH, J = 8.8 Hz), 7.09-7.30 (m, 5H), 5.23-5.39 (m, IH), 4.60-5.00 (m, 2H), 4.46-4.57 (m, IH), 2.56-2.94 (m, 2H), 2.29-2.39 (m, IH), 1.64-1.94 (m, 3H), 1.26-1.50 (m, 2H), 0.98-1.08 (m, IH), 0.92 (t, 3H, J = 7.4 Hz), 0.84-0.96 (m, 2H), 0.78 (dd, 6H, J = 6.4, 16.6 Hz). [α]_d = +30.4°

Example 4

The desired compound was prepared by coupling of 2ς andR-2-( -butyl)-succinic acid-4-t- butyl ester according to the method of Example 2C, followed by hydrolysis of the tert-butyl ester using the method of Example IE. mp 110 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 12.08 (s, IH), 11.92 (d, IH, J = 2.7 Hz), 8.43 (d, IH, J = 8.5 Hz), 8.30 (d, IH, J = 3.1 Hz), 8.16-8.19 (m, IH), 7.44-7.47 (m, IH), 7.11-7.30 (m, 8H), 5.32-5.42 (m, IH), 2.87-3.19 (m, 2H), 2.61- 2.74 (m, IH), 2.04-2.25 (m, 2H), 1.18-1.40 (m, 2H), 0.97-1.08 (m, IH), 0.69 (dd, 6H, J = 6.5, 16.3 Hz). MS (APCI) m/e 421 (M+l), 438 (M+18). Anal calcd for C25H28N2O4 • 0.5H2O: C, 69.90; H, 6.80; N, 6.52. Found: C, 69.83; H, 6.80; N, 6.49. [α]_d = +7.2°.

Example 5

Example 5A

A pH 4 solution in 1.5: 1 THF-H2O of the compound of Example 4 (50 mg, 1.0 x 1(H mmol) and 0-benzylhydroxylamine hydrochloride (26 mg, 1.6 x 10^"^ mmol) was cooled to 0 °C and EDCI (63 mg, 3.3 x 10^"! mmol) was added. The reaction stirred at 0 °C for 1 hour. The ice bath was removed and the reaction mixture was warmed to ambient temperature and stirred overnight The THF was removed in vacuo and the remaining liquid was partioned between EtOAc and citric acid. The organic layer was washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Flash chromatography (1 % MeOH-CH2Cl2) gave the desired product 5a in 46% yield. Example 5B

A mixture of benzyl hydroxamate 5a (0.266 g, 5.1 x IO"⁴ mol) and Pd/C (0.133 g) in 10 mL of THF was stirred overnight under 1 atm of H2- The reaction mixture was gravity filtered through a plug of celite. Solvent was removed in vacuo to give the desired product in 82% yield as a tan solid, mp 120 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.94 (s, IH), 10.33 (s, IH), 8.71 (s, IH), 8.47 (d, IH, J = 8.5 Hz), 8.33 (s, IH), 8.16-8.20 (m, IH), 7.44-7.48 (m, IH), 7.11- 7.31 (m, 7H), 5.30-5.39 (m, IH), 2.89-3.16 (m, 2H), 2.64-2.77 (m, IH), 1.83 (d, 2H, J = 7.4 Hz), 1.29-1.40 (m, IH), 1.14-1.26 (m, IH), 0.86-0.97 (m, IH), 0.66 (dd, 6H, J = 6.6, 10.3 Hz). MS (Cl) m/e 436 (M+l). Anal calcd for C25H29N3O4 • 1.00 H2O: C, 66.20; H, 6.88; N, 9.26. Found: C, 66.34; H, 6.74; N, 8.99. [α]_d = -11.5°.

Example 6

The desired compound was prepared by coupling of 2c and succinate ester 5 according to the method of Example 2C, followed by hydrolysis of the tert-butyl ester using the method of Example IE, and conversion of the acid to the hydroxamate according to the method of Example 5. mp 185 °C. *H NMR (300 MHz, DMSO-d6) δ 11.94 (d, IH, J = 2.6 Hz), 10.35 (s, IH), 8.70 (s, IH), 8.53 (d, IH, J = 8.8 Hz), 8.35 (d, IH, J = 3.4 Hz), 8.20-8.23 ( , IH), 7.46-7.51 (m, IH), 7.10-7.31 (m, 7H), 6.70 (dd, 4H, J = 8.1, 25.7 Hz), 5.33-5.43 (m, IH), 2.87-3.19 (m, 2H), 2.61-2.75 (m, IH), 2.14-2.44 (m, 2H), 2.14 (s, 3H), 1.88 (d, 2H, J = 7.3 Hz), 1.11-1.42 (m, 4H). MS (Cl) m/e 512 (M+l). Anal calcd for C31H33N3O4 * 0.75 H2O: C, 70.90; H, 6.62; N, 8.00. Found: C, 71.20; H, 6.63; N, 7.72. [α]_d = -5.8°.

The desired compound was prepared by coupling of 2c and succinate ester 6 according to the method of Example 2C, followed by hydrolysis of the tert-butyl ester using the method of Example IE. 1H NMR (300 MHz, DMSO-d6) δ 12.01 (d, IH, J = 3.0 Hz), 8.63 (d, IH, J = 9.2 Hz), 8.49 (d, IH, J = 3.3 Hz), 8.25-8.22 (m, IH), 7.52-7.48 (m, IH), 7.37-7.13 (m, 7H), 6.68 (dd, 4H, J = 34.2, 8.1 Hz), 5.7405.61 (m, IH), 5.52-5.45 (m, IH), 4.97-4.87 (m, 2H), 3.91 (br, IH), 3.16-2.92 (m, 2H), 2.40-2.10 (m, 4H), 2.15 (s, 3H), 1.87-1.63 (m, 2H), 1.44-0.96 (m, 7H), 0.84-0.70 (m, IH). MS (Cl) m/e 565 (M+l). Anal calcd for C36H40O4N2 • 1.5 H2O: C, 73.07; H, 7.32; N, 4.73. Found: C, 73.13; H, 6.97; N, 4.98.

The desired compound was prepared according to the method of Example 5, except substituting the compound of Example 7 for the compound of Example 4. mp 220 °C. 1H NMR (300 MHz, DMSO-d6) δ 12.02 (s, IH), 10.48 (s, IH), 8.77 (s, IH), 8.60 (d, IH, J = 9.2 Hz), 8.53 (s, IH), 8.29-8.26 (m, IH), 7.56-7.15 (m, 8H), 6.70 (dd, 4H, J = 34.6, 7.8 Hz), 5.80- 5.64 (m, IH), 5.55-5.44 (m, IH), 5.02-4.90 (m, 2H), 3.23-2.90 (m, 2H), 2.44-2.28 (m, 3H), 2.19 (s, 3H), 2.08-1.96 (m, IH), 1.91-1.66 (m, 2H), 1.48-0.96 (m, 7H), 0.76-0.63 (m, IH). MS (ESI) m/e 580 (M+l), 602 (M+Na). Anal calcd for C36H41N3O4 • 1.25 H2O: C, 71.79; H,

7.28; N, 6.97. Found: C, 71.59; H, 7.05; N, 7.06. [α]_d = -20.4°.

Example 9A

The desired compound was prepared according to the method of Examples 1A-C, except substituting L-tert-leucine for L-phenylalanine.

Example 9B

The desired compound was prepared according to the method of Examples 2B and C, except substituting 9_a for 2c and substituting succinate ester 2 for succinate ester 4. mp 218 °C (dec). ^lU NMR (300 MHz, DMSO-d6) δ 11.92 (s, IH), 10.45 (s, IH), 8.73 (s, IH), 8.36 (d, IH, J = 3.1 Hz), 8.17-8.21 (m, IH), 8.12 (d, IH, J = 8.8 Hz), 7.44-7.47 (m, IH), 7.13-7.25 (m, 2H), 5.54-5.70 (m, IH), 5.10 (d, IH, J = 8.8 Hz), 4.87-4.97 (m, 2H), 2.73 (dt, IH, J = 2.7, 10.9 Hz), 2.23-2.37 (m, IH), 1.98-2.20 (m, 2H), 1.28-1.39 (m, IH), 0.96-1.16 (m, IH), 1.00 (s, 9H), 0.82-0.94 (m, IH), 0.62 (dd, 6H, J = 6.1, 40.3 Hz). MS (DCI) m/e 442 (M+H)+. Anal calcd for C25H35N3O4 • 0.5 H2O: C, 66.64; H, 8.05; N, 9.32. Found: C, 66.59; H, 8.01;

N, 9.10. [α]_d = -55.9°.

Example 10A

Pentafluorophenol ester Qa (0.605 g, 1.53 mmol), prepared as described in WO94/02446, and ic (0.448 g, 1.70 mmol) were combined in dry DMF (6 mL). The solution was heated at 30 °C for 24 hours, then reduced in volume by rotary evaporation under high vacuum. The residue was diluted with ethyl acetate, then washed succesively with brine, pH3 buffer, aqueous Na2CO3, pH7 buffer and brine. The organics were dried over Na2SO4 and evaporated to give 10b (0.764 g) as a tan solid which was carried forward without purification.

Example 10B

To a 0 °C solution in THF (12 mL) of dioxolanone 3 (0.728 g, 1.5 mmol) was added 2.1 M HCl (12 mL) and the solution allowed to warm to ambient temperature over 18 hours. The solution was evaporated to drynessto give a tan foam (0.70 g). The crude material was purified by reverse phase HPLC to give the desired compound (0.223 g) as a white foam. 1H NMR (DMSO- d6) 0.65 (d, 3H, J = 6.4 Hz), 0.72 (d, 3H, J = 6.5 Hz), 1.02 (m, IH), 1.23 (m, IH), 1.41 (m, IH), 2.62 (m, IH), 2.94 (dd, IH, J = 7.4, 13.9 Hz), 3.17 (dd, IH, J = 6.5, 13.9 Hz), 3.91 (d, IH, J = 7.1 Hz), 5.38 (m, IH), 7.22 (m, 6H), 7.45 (dd, IH, J = 2.3, 6.4 Hz), 8.16 (dd, IH, J = 2.3, 6.1 Hz), 8.27 (d, IH, J = 3.0 Hz), 8.41 (d, IH, J = 3.0 Hz), 8.58 (bds, IH), 11.91 (d, IH, J = 2.7 Hz). MS (DCJ/NH3) M/e 454 (M+NH4)⁺, 437 (M+H)⁺, 419, 265. Anal. Calcd for C25 H28 N2 O5 ».75 H2O: C, 66.72; H, 6.61; N, 6.22. Found: C, 66.71; H, 6.30; N, 5.90.

Example 11

The desired compound was the slower eluting species in the chromatography described in Example 1. 1H NMR (DMSO-d6) 0.63 (d, 3H, J = 5.5 Hz), 0.71 (d, 3H, J = 5.5 Hz), 0.87 (m, 2H), 1.27 (m, IH), 2.59 (m, IH), 2.89 (dd, IH, J = 10.0, 13.6 Hz), 3.09 (dd, IH, J = 4.7, 13.6 Hz), 3.83 (d, IH, J = 7.8 Hz), 5.43 (m, IH), 7.21 (m, 4H), 7.32 (d, 2H, J = 6.9 Hz), 7.46 (dd, IH, J = 1.8, 5.5 Hz), 8.21 (dd, IH, J = 2.6, 5.5 Hz), 8.47 (d, IH, J = 3.3 Hz), 8.64 (d, IH, J = 8.9 Hz), 11.98 (d, IH, J = 2.6 Hz). MS (DCI/NH3) m/e 454 (M+NH4)+, 437 (M+H)+, 265. Anal calcd for C25H28 2O5: C, 68.79; H, 6.47; N, 6.42. Found: C, 67.87; H, 7.14; N, 5.54.

Example 12

The desired compound was prepared according to the method of Example 5, except substituting the compound of Example 10 for the compound of Example 4. mp 122-125 °C. H NMR (DMSO-d6) 0.63 (d, 3H, J = 6.8 Hz), 0.68 (d, 3H, J = 6.4 Hz), 0.85 (m, IH), 1.08 (d, IH), 1.37 (m, IH), 2.63 (m, IH), 2.94 (dd, IH, J = 6.8, 13.9 Hz), 3.18 (dd, IH, J = 7.2, 13.9 Hz), 3.77 (dd, IH, J = 6.8, 8.5 Hz), 5.22 (d, IH, J = 6.8 Hz), 5.37 (dd, IH, J = 6.8, 7.2 Hz), 7.19 (m, 6H), 7.45 (dd, IH, J = 0.7, 7.8 Hz), 8.13 (dd, IH, J = 2.0, 5.7 Hz), 8.25 (d, IH, J = 2.0 Hz), 8.37 (d, IH, J = 8.1 Hz), 8.83 (s, IH), 10.59 (s, IH), 11.92 (s, IH). MS (DCI/NH3) m/e 469 (M+NH4)⁺, 452 (M+H)⁺. Anal calcd for C25H29N3θ5»0.33 H2O: C, 65.64; H, 6.53; N, 9.19. Found: C, 65.65; H, 6.54; N, 8.20. [α]_d = +12 ° (C = 0.95, CH3OH).

Example 13

The desired compound was prepared according to the method of Example 5, except substituting the compound of Example 11 for the compound of Example 4. mp 172-175 °C. 1H NMR (DMSO-d6) 0.62 (d, 3H, J = 6.4 Hz), 0.69 (d, 3H, J = 6.1 Hz), 0.79 (m, IH), 0.88 (m, IH), 1.23 (m, IH), 2.62 (m, IH), 2.90 (dd, IH, J = 9.5, 13.9 Hz), 3.09 (dd, IH, J = 4.7, 13.9 Hz), 3.68 (dd, IH, J = 6.5, 8.8 Hz), 5.01 (d(OH), IH, J = 6.1 Hz), 5.41 (m, IH), 7.22 (m, 5H), 7.30 (s, IH), 7.31 (dd, IH, J = 1.7, 7.0 Hz), 7.46 (dd, IH, J = 1.3, 8.5 Hz), 8.20 (dd, IH, J = 2.6, 8.5 Hz), 8.44 (d, IH, J = 9.5 Hz), 8.46 (s, IH), 8.75 (s, IH), 10.51 (s, IH), 11.92 (s, IH). MS (DCVNH3) m/e 469 (M+MH4)⁺, 452 (M+H)⁺, 391. Anal calcd for

C25H29N3θ5^0.33 H2O: C, 65.64; H, 6.53; N, 9.19. Found: C, 65.63; H, 6.74; N, 8.31. [α]_d = -9.1 ° (C = l. l, CH3OH).

Example 14

The desired compound was prepared according to the method of Examples 10 and 12, except substituting 9a for ic. mp 144-146 °C. 1H NMR (DMSO-d6) 0.65 (d, 3H, J = 6.8 Hz), 0.69 (d, 3H, J = 6.5 Hz), 0.89 (m, IH), 0.98 (s, 9H), 1.20 (m, IH), 1.41 (m, IH), 2.77 (m, IH), 3.73 (t, IH, J = 8.2 Hz), 5.12 (d, IH, J = 9.5 Hz), 5.24 (d, IH, J = 8.1 Hz), 7.12 (m, 2H), 7.46 (d, IH, J = 6.8 Hz), 7.78 (d, IH, J = 9.4 Hz), 8.21 (dd, IH, J = 1.7, 6.1 Hz), 8.36 (d, IH, J = 2.7 Hz), 8.84 (bds, IH), 10.59 (bds, IH), 11.96 (bds, IH). 1 C NMR (DMSO-d6) 21.58, 23.49, 25.12, 27.05, 34.42, 37.22, 47.57, 60.23, 71.47, 112.07, 116.61, 121.45, 121.68, 122.81, 125.49, 134.45, 136.59, 168.77, 172.44, 193.57 . MS (DCI/NH3) m/e 435 (M+NH4)+, 418 (M+H)⁺ Anal calcd for C22H3lN3θ5»0.5 H2O: C, 61.95; H, 7.56; N, 9.95. Found: C, 61.64; H, 7.69; N, 9.67. [α]_d = -57 ° (C = 1.2, CH3OH).

Example 15

The desired compound was prepared according to the method of Examples 3A-E, except substituting phenyllithium for ethylmagnesium bromide.

Example 15B

The desired compound was prepared according to the method of Examples 10 and 12, except substituting 15a for ic. 1H NMR (CD3OD) δ 0.78 (d, 3H, J = 6.5 Hz), 0.80 (d, 3H, J =

6.5 Hz), 1.10 (m, IH), 1.30 (m, IH), 1.54 (m, IH), 2.77 (m, IH), 3.01 (dd, IH, J = 6.5, 13.6 Hz), 3.20 (dd, IH, J = 6.8, 13.9 Hz), 3.98 (d, IH, J = 7.1 Hz), 5.73 (t, IH, J = 6.8 Hz), 7.18 (m, 5H), 7.45 (t, 2H, J = 7.8 Hz), 7.58 (m, IH), 7.93 (d, 2H, J = 7.1 Hz). MS (DCVNH3) m/e 430 (M+NH4)+, 413 (M+H)+. Anal calcd for C23H28 2θ5»0.5H2θ: C, 65.54; H, 6.93; N, 6.65. Found: C, 65.57; H, 6.99; N, 6.52.

The desired compound was prepared according to the method of Example 1, except substituting 1 -methylindole for indole. *H NMR (300 MHz, DMSO-d6) δ 10.36 (s, IH), 8.68- 8.46 (m, 3H), 8.32-8.18 (m, IH), 7.56-7.18 (m, 7H), 5.43-5.33 (m, 2H), 4.82-4.6 (m, 2H), 3.88 (s, 3H), 3.12-3.07 (m, IH), 2.95-2.90 (m, IH), 2.40-2.39 (m, IH), 2.03-1.88 (m, 2H), 1.34-1.26 (m, 2H), 0.81-0.56 (m, 7H). MS (DCI/NH₃) m/e 490 (M+H)⁺. Anal calcd for C29H₃₅N_3O4»0.25 H₂O: C, 70.49; H, 7.24; N, 8.42. Found: C, 70.39; H, 7.37; N, 8.35.

Example 17A

To a -78 °C solution of N-Boc-phenylalanine (2.69 g, 10 mmol) in 10 mL THF was added MeLi (22.9mL, 32mmoL, 1.4M in ether) via addition funnel over 10 minutes. The cold bath removed and the solution allowed to warm to ambient temperature and stirred 2 hours. The reaction was quenched with 25 mL of 2N HCl solution, stirred for 10 minutes, and the aqueous layer was extracted with ether (3x). The combined organics were washed with brine, dried (Na2SO₄) and concentrated in vacuo. Flash chromatography (hexane-ethyl acetate 5:1) gave 17a (1.3 lg) as a waxy solid.

A 0 °C solution of i7a (1.31 g, 4.83 mmol) in 4N HCl/dioxane was stirred for 2 hours and then was diluted with diethyl ether. The residual sohd was filtered and dried under high vacuum to give 17_b (0.9 g) as the HCl salt.

The desired compound was prepared according to the method of Examples 1D-F, except substituting 17b for ic. mp 180 °C (dec). iH NMR (DMSO-D6) δ 10.37 (S, IH), 8.71 (S, IH), 8.47-8.38 (D, IH, J = 8.1 Hz), 7.30-7.13 (M, 5H), 5.36-5.30 (M, IH), 4.80-4.06 (M, 3H), 3.10-3.04 (M, IH), 2.72-2.64 (M, IH), 2.41-2.39 (M, IH), 2.11 (S, 3H), 1.92-1.90 (M, IH), 1.79-1.70 (M, IH) 1.39-1.35 (M, 2H), 1.23-1.20 (M, 2H), 0.84-0.75 (M, 7H). MS (DCI/NH3) m/e 375 (M+H). Anal calcd for C2iH₃oN₂O C: C, 67.35; H, 8.01; N, 7.48. Found: C, 66.95; H, 8.01; N, 7.31.

To a cold 0 °C solution of bromobenzene (5 g, 32 mmol) in THF was added nBuLi (12.8 mL, 32 mmol, 2.5M in diethyl ether) over the course of 5 minutes. The resulting yellow solution was stirred at 0 °C for 25 minutes and then was added to a -78 °C solution of N-BOC-1- phenylalanine (2.69 g, 10 mmol) over 25 minutes. The resulting yellow solution was allowed to warm to room temperature overnight (16 hours) and then was quenched with IN HCl solution. The aqueous layer was extracted with ether (3x) and the combined organics were washed with IN NaHCO₃ and brine, dried (MgSO4) and concentrated in vacuo.. Flash chromatography (hexane- ethyl acetate 6:1) gave !8a (0.25 g) as a waxy solid.

Example 18B

The desired compound was prepared according to the method of Examples 17B and C, except substituting 18a for i7a. mp 209-211 °. IH NMR (DMSO-d6) δ 10.39 (s, IH), 8.72 (s, IH), 8.59-8.57 (d, IH, J=8.5 Hz), 8/06-8.02 (d, 2H, J=8.1 Hz), 7.69-7.64 (t, IH, J=7.1Hz), 7.55-7.52 (t, 2H, J=8.1 Hz), 7.40-7.38 (d, 2H, J=7.4 Hz), 7.30-7.28 (m, 2H), 7.20-7.18 (m, IH), 5.66-5.62 (m, IH), 5.44-5.35 (m, IH), 4.86-4.70 (m, 2H), 3.19-3.13 (dd, IH, J=7.9,4.1 Hz), 2.94-2.86 (m, IH), 2.38-2.34 (m, IH), 1.96-1.81 (m, 2H), 1.33-1.26 (m, 2H), 0.88-0.81 (m, 2H), 0.68-0.59 (m, 6H). MS (DCI/NH4) 437 (M+l). Anal. Calcd for: C26H₃2N₂O₄: C, 70.57; H, 7.44; N, 6.33. Found: C, 70.60; H, 7.13; N, 6.42.

Example 19

The desired compound was prepared according to the method of Example 1 A, except substituting N-Boc-O-tBu-L-tyrosine for N-BOC-1-phenylalanine.

Example 19B

A cold 0 °C solution of 19a (1.8 g, 4.7 mmol) in trifluoroacetic acid was stirred for 30 minutes. The excess TFA was removed in vacuo and the residue was taken up in IN HCl in Et2θ, allowed to stir for 30 minutes, diluted with diethyl ether, and the residual solid was filtered. The extremely hygroscopic solid was dried in a vacuum oven for several hours and then was dried under high vacuum for 16 hours to give 19b (0.48 g) as a hygroscopic, white HCl salt. Example 19C

To a 0 °C solution of succinate ester 3 (1.5 g, 5mmol) in 20 mL of methylene chloride was added HOBT (0.81 g, 6 mmol) and EDCI (1.17 g, 6 mmol). The suspension became a clear solution after 10 minutes and was allowed to stir for 4 hours total. The solution was diluted with methylene chloride and the organics were washed with water (3x) and brine and concentrated in vacuo. The crude HOBT ester was dissolved in DMF (lOmL) and added to a solution of 19b ( 1.7 g, 6 mmol) and NMM (1.2 g, 10 mmol) in 10 mL of DMF. The reaction stirred for 3 days and then was diluted with ethyl acetate and the organic layer was washed with water (3x) and brine, dried (Na2SO4) and concentrated in vacuo. Flash chromatography (gradient elution: methanol- methylene chloride 0-2%) gave 19c (2.45 g) as a while solid.

Example 19D

The desired compound was prepared according to the method of Examples IE and F, except substituting 19c for id. mp 208-210 °C (dec). ^lH NMR (300 MHz, DMSO-d6) δ 10.42 (s, IH), 9.15 (s, IH), 8.71 (s, IH), 8.49-8.47 (d, IH, J = 7.8 Hz), 7.99-7.97 (d, 2H, J = 7.4 Hz), 7.63-7.60 (t, IH, J = 7.2 Hz), 7.53-7.48 (t, 2H, J = 7.8 Hz), 7.13-7.10 (d, 2H, J = 8.2 Hz), 6.65-6.62 (d, 2H, J = 8.5 Hz), 5.73-5.64 (m, IH), 5.49-5.48 (m, IH), 4.95-4.86 (m, 2H), 3.01-2.95 (m, IH), 2.77-2.69 (m, IH), 2.36-2.34 (m, IH), 1.89-1.68 (m, 3H), 1.28-1.18 (m, 5H), 0.82-0.58 (m, 7H). MS (DCI/NH₃) m/e 481 (M+H)⁺.

The desired compound was prepared according to the method of Example 19, except substituting N-BOC-alpha-cyclohexyl alanine for N-Boc-O-tBu-L-tyrosine. mp 209-210 °C. *H NMR (300 MHz, DMSO-d6) δ 10.47 (s, IH), 8.76 (s, IH), 8.54-8.52 (d, IH, J = 7.5 Hz), 7.92-7.89 (d, 2H, J = 8.1 Hz), 7.66-7.60 (t, IH, J = 8.5 Hz), 7.55-7.49 (t, 2H, J = 7.8 Hz), 5.62-5.50 (m, IH), 5.33-5.29 (m, IH), 4.93-4.86 (m, 2H), 2.20-2.08 (m, 2H), 1.91-1.87 (m, 2H), 1.61-1.32 (m, 7H), 1.13-1.10 (m, 4H), 0.9-0.80 (m, 3H), 0.76-0.74 (d, 3H, J = 6.4 Hz), 0.67-0.65 (d, 3H, J = 6.8 Hz). MS (DCI/NH₃) m/e 443 (M+H)⁺. Anal calcd for C26H₃8N₂O₄: C, 70.55; H, 8.65; N, 6.32. Found: C, 70.21; H, 8.65; N, 6.32.

Example 21

Example 21 A

21a

To a -40 °C solution under nitrogen of methylmagnesium bromide (9.54 ml, 3.0 M in

Et2θ, 28.6 mmol) in dry toluene (20 ml) was added pyrrole (3.2 ml, 46.5 mmol) dropwise and the resulting solution was stirred at -10 °C for 10 minutes. The Grignard reagent was cannulated into a solution of BOC-L-phenylalanine-methyl ester (1.0 g, 3.58 mmol) in dry toluene (10ml) at -65 °C, the temperature was allowed to warm up to 0 °C over 4 hours, and the reaction was quenched by addition of sat. NH4CI solution, extracted with CH2CI2 (3x), dried over Na2SO4, filtered and concentrated in vacuo to give 1.9 g of a crude mixture which was purified by flash chromatography(15% ethyl acetate-hexane) followed by recrystallization from Et2θ-hexanes to give 21a (677 mg) as a white solid.

Example 2 IB

21a 21b

A solution of 21a (600 mg, 1.91 mmol) in 4M HCl/dioxane (8 ml) was stirred at room temperature for 50 minutes. The solvent was evaporated to give 21b (507 mg) as a purple solid which was used in the next step without further purification.

Example 2 IC

To a 0 °C solution in DMF (20 mL) of 21b (600 mg, 1.91 mmol) was added HOBT (258 mg, 1.91 mmol), NMM(630 μl, 1.91 mmol), succinate ester 2 (515.7 mg, 1.91 mmol) and EDC (366 mg, 1.91 mmol) and the reaction mixture was stirred for 20 minutes at 0 °C and for 15 hours at ambient temperature. The reaction mixture was diluted with ethyl acetate and washed with brine-H2θ (1:1). The aqueous wash was extracted with ethyl acetate (3x) and the combined organic extracts were washed with brine- H2O (1:1), dried over Na2S04, filtered and concentrated in vacuo to give a brown foam. Purification by chromatography on silica gel (20% ethyl acetate- hexanes to give 21c (797 mg) as a yellow foam. Example 21D

A solution of 2l£ (781mg, 1.67 mmol) in trifluoroacetic acid (8ml) was sthred at ambient temperature for 50 minutes. The ssolvent was evaporated to give 21d (808 mg) as a yellow foam.

Example 21E

To a 0 °C solution in DMF (15 mL) under nitrogen of 2Td (753 mg, 1.84 mmol) was added

HOBT (273 mg, 2.02 mmol), NMM(443 μl, 4.04 mmol), TBDMSONH2 (298 mg, 2.02 mmol) and EDC (387 mg, 2.02 mmol). The reaction mixture was stirred at 0 °C for 1 hour and at ambient temperature for 17 hours. The reaction mixture was diluted with ethyl acetate and washed with brine-H2θ (1:1). The aqueous wash was extracted with ethyl acetate (3x) and the combined organic extracts were washed with brine-H2θ (1:1), dried over Na2S04, filtered and concentrated in vacuo to give a yellow solid. Purification by chromatography on silica gel (10% MeOH- CH2CI2) gave the desired compound (448 mg) as a white solid, mp 204-205 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 0.65 (d, 3H, J = 3 Hz), 0.77 (d, 3H, J = 3 Hz),0.83 (m, IH), 1.13- 1.38 (m, 3H), 1.77-1.98 (m, 2H), 2.41 (dt, IH, J = 3, 12 Hz), 2.88 (dd, IH, J = 3, 10.5Hz), 3.07 (dd, IH, J = 4.5, 15 Hz), 4.66-4.84 (m, 2H), 5.23-5.46 (m, 2H), 6.22 (m, IH), 7.09-7.40 (m, 7H), 8.44 (d, IH, J = 9 Hz), 8.685 (s, IH), 10.36 (s, IH), 11.88 (s, IH). MS (DCI/NH3) m/z 426 (M+H)+. [α]_d =+19.69°(EtOH).

22a

To a -78 °C solution under nitrogen of n-butyl hthium (2.5M in hexanes, 21.5 ml, 53.8 mmol) in ether (180ml) was added 3-bromopyridine (5.18 ml, 53.8 mmol) dropwise and the reaction mixture was stirred for 1 hour. A solution of BOC-L-phenylalanine methyl ester (6.0 g, 21.5 mmol) in ether (25 ml) was added and the reaction mixture was stirred at -78 °C for 3 hours and 0 °C for two hours. The reaction mixture was poured onto water, extracted with CH2CI2 (3x), dried over Na2SO4, filtered and concentrated in vacuo to give an orange oil which was purified by flash chromatography (30% ethyl acetate-hexanes) to give 22a (1.2 g) as a yellow oil.

Example 22B

The desired compound was prepared according to the method of Examples 21B-E, except substituting 22a for 21a. mp 196.3-197.7 °C. *H-NMR (300 MHz, DMSO-d6) δ 0.49-0.62 (m, 6H), 0.69-0.82 (m, 2H ), 1.04-1.28 (m, 2H), 1.66-1.80 (m, IH), 1.825-1.97 (m, IH), 2.23- 2.35 (m, IH ), 2.84-2.98 (m, IH), 3.08-3.21 (m, IH), 4.62-4.84 (m, 2H), 5.24-5.63 (m, 2H), 7.09-7.38 (m, 6H), 7.49-7.57 (m, IH), 8.26-8.37 (IH), 8.61-8.78 (3H), 9.07-9.15 (IH). MS (DCI/NH3) m/z 438 (M+H)+. α]_d =-18.86° (EtOH).

23a

To a -78 °C solution under nitrogen of 1-triisopropylsilylpyrrole (2.8 g, 12.6 mmol) in THF (30 ml) was added NBS (2.23 g, 12.6 mmol) via a sohd addition funnel. The reaction mixture was stirred at -78 °C for 1 hour and then was warmed to ambient temperature over 1 hour. The reaction mixture was concentrated, carbon tetrachloride was added to precipitate the succinimide and the solid was filtered and washed with carbon tetrachloride. The filtrate was concentrated, and the crude product was purified by flash chromatography (hexanes) to afford 3- bromo- 1-triisopropylsilylpyrrole (3.18 g) as a colorless oil.

23a 2b

To a -78 °C solution under nitrogen of 3-bromo-l-(triisopropylsilyl-pyrrole (3.18 g, 10.5 mmol) in dry THF (50 ml) was added n-BuLi (1.6 M, 6.56 ml, 10.5 mmol) and the reaction mixture was stirred for 0.5 hours. A solution of BOC-L-phenylalanine methyl ester (1.25 g, 4.2 mmol) in dry THF (2 ml) was then added and the resulting mixture was stirred at -78 °C for 1.5 hours. The reaction mixture was poured onto water, extracted with CH2CI2 (3x), dried over Na2SO4, filtered, and concentrated in vacuo. Chromatography on silica gel (10% ethyl acetate- hexanes) provided 23b (268 mg) as a light yellow oil. Example 23C

The desired compound was prepared according to the method of Examples 21B-E, except substituting 23b for 21a. ^lH NMR (300 MHz, DMSO-d6) δ 0.53-0.88 (7H), 1.06-1.36 (m, 2H), 1.73-2.13 (m, 2H), 2.32-2.46 (m, IH), 2.70-2.91 (m, IH), 2.98-3.08 (m, IH ), 4.65-4.85 (m, 2H), 5.18-5.54 (m, 2H), 6.54 (IH), 6.85 (IH), 7.09-7.40 (m, 5H), 7.75 (IH), 8.34-8.54 (IH), 8.70 (s, IH). MS (DCI/NH3) m/z 426 (M+H)⁺.

Example 24

24a

To a -78 °C solution under nitrogen of BOC-L- phenylalanine methyl ester (2.0 g, 7.16 mmol) in dry THF (80 ml) was added 2-thienyllithium ( 17.9 ml, 17.9 mmol) and the reaction mixture stirred for 1 hour. The reaction mixture was poured onto water, extracted with CH2CI2 (3x), dried over Na2SO4, filtered and concentrated in vacuo to give an orange oil. Purification by chromatography on silica gel (0.5% acetone-CH2Cl2) gave 24a (882 mg) as a yellow solid. Example 24B

The desired compound was prepared according to the method of Examples 21B-E except substituting 2ia for 2ia. 1H NMR(300 MHz, DMSO-d6) δ 0.54-0.87 ( , 7H), 0.95-1.35 (m, 2H ),1.68-2.11 (m, 2.5H), 2.32-2.47 (m, 0.5H), 2.83-3.15 (m, 2H), 4.63-4.85 (m, 2H), 5.29- 5.52 (m, 2H), 7.11-7.40 (m, 6H), 8.02-8.20 (2H), 8.58-8.75 (IH), 8.73 (s, IH). MS (DCI/NH3), m/z 443 (M+H)⁺.

Example 25

25a

To a -70 °C solution under nitrogen of oxazole (3.36 g, 48.8 mmol) in THF (80 ml) at was added n-BuLi (30.5 ml, 48.8 mmol) and the mixture was stirred at -70 °C for 20 minutes. A solution of N-BOC-phenylalaninal (4.86 g, 19.5 mmol) in THF (20 ml) was then added and the mixture was stirred at -50- -70 °C for 6 hours. The reaction was quenched with H2O, extracted with CH2CI2 (3x), dried over Na2SO4, filtered and concentrated in vacuo. Chromatography on silica gel (40% ethyl acetate-hexanes) provided 5a (1.12 g). Example 25B

To a 0 °C solution of 2 a (969 mg, 3.05 mmol) in CH2CI2 (60ml) was added KBr/H2θ (36.3 mg, 613μl) and 2,2,6,6-tetramethyl-l-piperidinyloxy, free radical (4.76 mg, 0.0305 mmol). In another vial, NaOCl solution (10.9 ml) was adjusted to pH 8 with saturated aqueous NaHCO3 solution, and the resulting solution was added to the 25a solution and the reaction mixture was stirred at 0 °C for 5 hours. The reaction mixture was poured into H2θ-brine, extracted with CH2CI2 (3x), dried over Na2SO4_; filtered and concentrated in vacuo. Chromatography on silica gel (30%-40% ethyl acetate-hexanes) gave 25b (731 mg).

Example 25C

The desired compound was prepared according to the method of Examples 21B-E except substituting 25b for 21a. ^H NMR (300 MHz, DMSO-d6) δ 0.54-0.90 (m, 7H), 1.14-1.39 ( , 3H ), 1.75-2.06 (m, 2H), 2.71-2.82 (m, IH), 3.1 1-3.22 (m, IH), 4.64-4.91 (m, 2H), 5.29-5.42 (m, 2H), 7.12-7.41 (m, 5H), 8.53 (d, IH, J = 7.5 Hz), 8.60-8.65 (IH), 8.74 (s, IH). 9.02-9.08 (IH), 10.36-10.48 (IH). MS (DCI/NH3) m/z 428 (M+H)⁺.

To a -78 °C solution under nitrogen of thiazole (1.1ml, 15.8 mmol) in THF (80 ml) was added n-butyl lithium (1.6M in hexanes, 9.88 ml, 15.8 mmol) and the reaction mixture was stined for 0.5 hours. A solution of BOC-L-phenylalanine methyl ester (2.0g, 7.17 mmol) in THF (5 ml) was added and the mixture was stirred at -78 °C for 30 minutes. The reaction mixture was poured into water, extracted with CH2CI2 (3x), dried over Na2SO4, filtered, and concentrated in vacuo.

Chromatography on silica gel (20% ethyl acetate-hexanes) gave 26a (1.95g) as a yellow solid.

Example 26B

The desired compound was prepared according to the method of Examples 21B-E except substituting 26a for 21a. ^!H NMR (300 MHz, DMSO-d6) δ 0.55-0.92 (m, 7H), 1.18-1.40 (m, 2H),1.80-2.29 (m, 3H), 2.75-2.90 (m, IH), 4.66-4.95 (m, 2H), 5.30-5.76 (m, 2H), 7.13-7.38 (m, 5H), 8.22-8.30 (2H), 8.58-8.75 (2H). MS (DCI/NH3) m/z 444 (M+H)+. Example 27

Example 27A

O H

O H O O H O ' 2Za

Malic acid (53.2 g, .397 mol) was dissolved in 400 mL of HCl saturated 2-propanol and the solution was heated at reflux for 22 hours. The solution was reduced in volume by rotary evaporation, diluted with EtOAc (1 L), and extracted twice with saturated aqueous Na2CO3. The organics were dried over MgSO4 and concentrated to give dπ^'-jo-propyl malate 27a (67g).

Example 27B

Diwo-propyl malate (27a, 25.6 g, 117 mmol) was added slowly to a 1 M solution of LDA in THF (235 mL, 235 mmol) at -78 °C. The solution was allowed to slowly warm to -50 °C over 2 hours, and then was recooled to -78 °C. Cinnamyl bromide (25.0g, 127 mmol) in THF (50 mL) was added dropwise, and the solution was stirred at -78 °C for 15 hours. The dry ice bath was removed and the reaction was quenched with IM HCl. The solution was diluted with ether and extracted twice with IM HCl. After drying (Na2SO4) and solvent removal, the crude material was chromatographed on silica gel (15% ether-hexanes) to give 27b as a 10:1 mixture of diastereomers (9.5 g).

A mixture of 27b (9.29g) and 10% Pd/C (0.45 g) and were placed in a Parr shaker containing 150 mL methanol, and exposed to 4 atm pressure of hydrogen for 18 hours. Filtration and solvent removal provided 27c as a yellow liquid (9.39 g).

Example 27D

A solution of 27c (9.39 g, 27.9 mmol) in 20 mL dioxane was treated with 3 M KOH (30 mL) and stirred overnight at 90 °C. The solution was poured over ice and acidified to pH 3 with concentrated HCl. The reaction mixture was extracted twice with EtOAc, and the organics were dried over MgSO4. Solvent removal gave 27d as a yellow liquid.

Example 27E

To a solution of 27_d (7.0 g, 28 mmol) DMF (50 mL) and 2,2-dimethoxypropane (180 mL) was added Dowex-50 resin and the mixture was stirred at ambient temp for 3 days. The resin was filtered off and the solution concentrated to give a DMF solution of 27e which was used as is in the next step.

Crude acid 2_7e (theoretical yield 28 mmol) with residual DMF was diluted with CH2CI2 (110 mL) and cooled to 0 °C. Pentafluorophenol (8.33 g, 45 mmol) was added, followed by EDCI (6.49 g, 33.8 mmol). The mixture was stirred at 0 °C for 2.5 hours, then extracted succesively with saturated aqueous Na2CO3 and brine. The organic phase was reduced in volume in vacuo, diluted with ethyl acetate, washed three times with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Chromatography on silica gel (gradient elution 10-15-20% ether- hexanes) gave 271 (8.88 g) as a 7:4 mixture of diastereomers.

Example 27G

The desired compound was prepared according to the method of Example 10, except substituting 271 for iOa. mp 111-113 °C. ^lH NMR (300 MHz, DMSO-d6) δ 1.23 (m, 3H), 1.37 (m, IH), 2.25 (m, IH), 2.38 (m, IH), 2.62 (m, IH), 2.90 (dd, IH, J = 6.6, 14.0 Hz), 3.21 (dd, IH, J =7.3, 13.6 Hz), 3.84 (dd, IH, J = 6.6, 8.5 Hz), 5.24 (d, IH, J = 6.6 Hz), 5.44 (q, IH, J = 8.1 Hz), 6.77 (dd, 2H, J = 1.5, 8.2 Hz), 6.96 (m, 3H), 7.15 (m, 3H), 7.22 (m, 6H), 7.47 (dd, IH, J = 1.9, 5.9 Hz), 8.19 (dd, IH, J = 2.2, 5.9 Hz), 8.32 (d, IH, J = 3.0 Hz), 8.52 (d, IH, J = 8.4 Hz), 8.83 (bds, IH), 10.63 (bds, IH), 1 1.94 (d, IH, J = 2.6 Hz). ¹ C NMR (CD₃OD) δ

30.03, 30.11, 36.55, 39.80, 50.99, 57.05, 73.04, 112.98, 116.67, 122.89, 123.37, 124.49, 126.50, 127.15, 127.50, 129.12, 129.20, 129.28, 130.45, 135.53, 138.43, 138.69, 143.14, 171.52, 175.07, 194.40. MS (APCI) m/e 514 (M+H)⁺, 453. Anal calcd for C₃₀H₃₁N₃O₅«0.8 H₂O: C, 68.24; H, 6.22; N, 7.96. Found: C, 68.40; H, 6.27; N, 7.56. [α]_d = -129 (CH₃OH, c = 0.02).

The desired compound was isolated in the purification of the compound of Example 27. mp 1 16-118 °C. *H NMR (300 MHz, DMSO-d6) δ 1.18 (m, 2H), 1.28 (m, IH), 1.53 (m, IH), 2.01 (m, 2H), 2.70 (m, IH), 2.89 (dd, IH, J = 4.1, 13.3 Hz), 3.12 (dd, IH, J = 4.8, 13.3 Hz), 3.97 (t, IH, J = 4.9 Hz), 5.21 (d, IH, J = 5.2 Hz), 5.38 (m, IH), 7.04 (d, 2H, J = 7.0 Hz), 7.1- 7.3 (m, 10H), 7.47 (m, IH), 8.20 (dd, IH, J =2.3, 5.6 Hz), 8.41 (d, IH, J = 2.9 Hz), 8.51 (d, IH, J = 8.5 Hz), 8.63 (bds, IH), 10.37 (bds, IH), 11.97 (bds, IH). MS (APCI) m/e 514 (M+H)+, 453 . Anal calcd for C₃₀H₃₁N₃O5»0.5 H₂O: C, 68.95; H, 6.17; N, 8.04. Found: C, 69.1 1; H, 6.17; N, 7.92. [α]_d = -22.3 (CH₃OH, c = 0.01).

Example 29

To a solution of 29a (0.32g, 1.08 mmol) in DMF (6.0 mL) was added EDC (0.23 g, 1.19 mmol), HOBT (0.16 g, 1.19 mmol), NMM (0.13 mL, 1,19 mmol) and 1,2-phenethyldiamine (0.12 g, 1.13 mmol) and the reaction mixture was stirred for 6 hours, the reaction mixture was partitioned between ethyl acetate and brine. The aqueous layer was separated and extracted twice with ethyl acetate. The ethyl acetate extracts were combined, washed with brine, dried over MgSO4, filtered and evaporated to dryness. The crude 29b was used for next reaction without purification.

Example 29B

A mixture of 29b and camphorsulfonic acid (12 mg, mmol) in toluene (20 mL) was heated at 80 °C for 4 hours. The reaction mixture was evaporated to a small volume and partitioned between CH2CI2, brine and saturated aqueous NaHCO₃. The aqueous layer was extracted with CH2CI2. The CH2CI2 layers were combined, dried (MgSO4), filtered and evaporated to dryness. Flash chromatography (40%-80% ethyl acetate-hexanes) gave 22c (261 mg) as white crystals.

22ε 29d

A mixture of 29c (255 mg, 0.69 mmol) and trifuloroacetic acid (1.5 mL) was stirred for 30 minutes, and then was evaporated to dryness. Residual trifluoroacetic was removed by azeotropic evaporation with toluene to give 29d as brownish crystals which was used without further purification.

Example 29D

To a solution of succinate ester 2 (0.828 mmol) in DMF (2 mL) was added EDC (159 mg, 0.828 mmol), HOBT(l 12 mg, 0.828 mmol) and NMM (0.19 mL, 1.73 mmol). The reaction mixture was stirred at room temperature for 10 minutes and a solution of 29d (0.69 mmol) in DMF (2 mL) was added. The reaction mixture was stirred for 10 hours and then was partitioned between ethyl acetate and brine. The aqueous layer was separated and extracted twice with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried (MgSO4), filtered and evaporated to dryness. Chromatography on silica gel (20-40 % ethyl acetate-hexanes) gave 29e (156 mg) as yellow crystals.

Example 29E

The desired compound was prepared according to the method of Example 25B, except substituting 22e for 25_a.

Example 29F

The desired compound was prepared according to the method of Examples 21D and E, except substituting 29f for 21c. Mixture of two stereoisomers: mp: 159.5-161.0 °C (dec). ^lH NMR (300 MHz, DMSO-d6) δ 0.58 (d, 3H, J = 5.6 Hz), 0.65 (d, 3H, J = 5.6 Hz), 0.72 (d, 3H, J = 6.2 Hz), 0.87 (d, 3H, J = 6.2 Hz), 0.79-0.89 (m, IH), 0.70-0.89 (m, IH), 1.20-1.30 (m, 2H), 1.30-1.42 (m, 2H), 1.83-2.17 (m, 3H), 1.83-2.17 (m, 3H), 2.78-2.87 (m, IH), 2.78-2.87 (m, IH), 3.40 (m, 2H), 3.45 (m, 2H), 4.70 (dd, IH, J = 16.5, 1.6 Hz), 4.81 (dd, IH, J = 10, 1.6 Hz), 4.88 (d, IH, J = 10.5 Hz), 4.89 (d, IH, J = 15.8 Hz), 5.38 (m, IH), 5.55 (m, IH), 5.79 (m, IH), 5.84 (m, IH), 7.21 (m, 2H), 7.26-7.32 (m, 5H), 7.41 (m, 2H), 7.36-7.43 (m, 5H), 7.58 (d, 2H, J = 8.4 Hz), 7.89 (d, 2H, J = 8.7 Hz), 8.61 (d, IH, J = 8.4 Hz), 8.70 (s, IH, J = 8.2 Hz), 8.72 (s, IH), 8.72 (s, IH), 10.40 (d, IH, J = 1.2 Hz), 10.42 (d, IH, J = 1.2 Hz), 13.52 (s, IH), 13.52 (s, IH). MS (DCI-NH3) m/e 477 (M+H)+, 433. Anal calcd for C27H32N4O4: C, 66.78; H, 6.84; N, 11.53. Found: C, 66.6; H, 6.69; N, 11.25. Example 30

Example 30A

To a solution of 30a (2.45 g, 5.15 x 10^"3 mol), prepared by coupling of 2c and/?-2-(/- butyl)-succinic acid-4-t-butyl ester according to the method of Example 2C, in pyridine (50 mL) was added O-methylhydroxylamine hydrochloride (0.80 g, 1.00 x 10^"^ mol) in one portion and the mixture was heated at 80 °C for 3 days. The pyridine was removed in vacuo. The residue was taken up in CH2CI2 and the solvent was removed in vacuo. Flash chromatography (CH2CI2) gave 30b as a mixture of oxime diastereomers.

Example 30B

The desired compound was prepared according to the method of Examples 5A and B, except substituting 30b for the compound of Example 4. 1H NMR (300 MHz, DMSO-d6) δ 11.43 (s, IH), 10.37 (s, IH), 8.73 (s, IH), 8.36 (d, IH, J = 8.1 Hz), 8.08 (d, IH, J = 7.7 Hz), 7.92 (d, IH, J = 2.6 Hz), 7.41-6.98 (m, 8H), 5.60-5.49 (m, IH), 3.90 (s, 3H), 3.20-2.98 (m, 2H), 2.81-2.69 (m, IH), 1.87-1.77 (m, 2H), 1.29-1.17 (m, IH), 1.02-0.74 (m, 2H), 0.58-0.49 (m, 6H). MS (DCI-NH3) m/e 465 (M+H)⁺. Anal calcd for C26H32N4O4-0.25 H2O: C, 66.57: H, 6.98; N, 11.94. Found: C, 66.72; H, 7.1 1; N, 1 1.85.

Example 31

Example 31 A

To a suspension in THF (25 mL) of OBn- Asp (1 g, 4.48 mmol) and activated charcoal (25 mg) was added diphospgene (0.416 mL, 3.45 mmol) via syringe at ambient temperature and the reaction mixture was heated at 55 °C for 1.5 hours. The solution was then filtered through celite, the filter cake was washed with EtOAc, and the solvent was removed in vacuo. The resulting solid was recrystallized (EtOAc-Hexane) to give the desired product in 55% yield.

Example 3 IB

The desired compound was prepared according to the method of Examples 2A and B, except substituting 3_la for 212 and substituting for R-2-(/-butyl)-succinic acid-4-t-butyl estersuccinate ester 4. Example 31 C

The desired compound was prepared according to the method of Example 5, except substituting lib for the compound of Example 4.

Example 32

Cyclohexylacetic acid (25 g, 0.176 mol) was dissolved in 50 mL thionyl chloride, and the solution was heated at reflux for 1 hour. The solution was concentrated in vacuo and placed under vacuum for 1 hour. The acid chloride was then added to a -78 °C solution in THF (450 mL) of 1- lithio 2-(S)-benzyloxazolidinone (0.158 mol). After 10 minutes, the dry ice bath was removed, and after a further 30 minutes, the mixture was quenched with aqueous NH C1 solution. The solution was extracted with 1 M NaOH and washed with pH 7 buffer solution. The organic phase was dried over MgSO4, filtered and concentrated in vacuo to give 32a as a white solid (42 g) which was used without further purification. Example 32B

To a -78 °C solution in THF (420 mL) of acyl oxazolidinone 32a (42 g, 140 mmol) was added sodium hexamethyldisilazide (140 mL of a 1 M soultion in THF, 140 mmol) dropwise over 40 minutes. After 30 minutes, a solution oftert-butyl bromoacetate (23 mL, 156 mmol) in 70 mL THF was added dropwise over 30 minutes. One hour after the addition was begun, the dry ice bath was removed and replaced with an ice bath. After 2 hours at 0 °C, the reaction was quenched with aquesou NR_tCl. The solution was concentrated, diluted with EtOAc and extracted twice with aqueous NH₄C1. After drying (Na2SO4) and solvent removal, the crude material was recrystalhzed from 3:1 hexanes-EtOAc to give 32b (31.8 g) as white needles, mp 141-142 °C. Flash chromatography of the mother liquors provided a further 2.60 g product.

Example 32C

To a 0 °C solution of acyloxazolidinone 32b (34.4 g, 83 mmol) in 360 mL THF was added 30 mL water and 33 ml 30% hydrogen peroxide, followed by a solution of LiOH (5.28 g, 126 mmol) in 120 mL water. After 6.5 hours, the peroxides were quenched with NaHSO₃ (300 mmol), then KOH (300 mmol) was added. The solution volume was reduced in vacuo and the pH adjusted to 9 with 50% aqueous NaOH. The solution was extracted twice with methylene chloride, then acidified to pH3 with concnetrated HCl. The aqueous phase was extracted with ethyl acetate. The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo to give 32c as a slightly yellow oil (10.4 g).

The desired compound was prepared according to the method of Example 19C, except substituting 32_c for succinate ester 3.

Example 32E

A solution of 32d (1.37 g, 2.86 mmol) in 30 mL HCl saturated acetic acid was stirred for 4 hours at ambient temperature. The reaction mixture was concentrated in vacuo and the residue was azeotroped twice with toluene. Vacuum drying provided the desired compound as a white foam. 1H NMR (300 MHz, CD₃OD) δ 0.87 (m, 2H), 1.08 (m, 2H), 1.42 (m, 3H), 1.60 (m, 4H), 2.5 (m, 3H), 2.87 (dd, IH, J = 6.7, 13.9 Hz), 3.07 (dd, IH, J = 6.8, 13.9 Hz), 5.62 (t, IH, J = 6.8 Hz), 6.61 (d, 2H, J = 8.4 Hz), 6.98 (d, 2H, J = 8.5 Hz), 7.42 (t, 2H, J = 7.4 Hz), 7.55 (m, IH), 7.89 (d, 2H, J = 7.2 Hz) . ¹³C NMR (CD₃OD) δ 27.40, 31.29, 31.66, 34.72, 37.81, 41.63,

49.11, 56.37, 116.15, 129.07, 129.61, 129.70, 131.45, 134.45, 137.18, 157.08, 176.06, 176.35, 200.32. MS (DCI/NH3) m/e 424 (M+H)+, 195.

The desired compound was prepared according to the method of Example 5, except substituting the compound of Example 33 for the compound of Example 4. mp 144-145 °C. Η NMR (300 MHz, DMSO-d6) δ 0.7-1.0 (bdm, 5H), 1.2-1.6 (bdm, 6H), 2.01 (m, 2H), 2.58 (m, IH), 2.76 (dd, IH, J = 7.4, 13.9 Hz), 2.97 (dd, IH, J = 6.8, 13.9 Hz), 5.39 (q, IH, J = 7.1 Hz), 6.59 (d, 2H, J = 8.5 Hz), 7.01 (d, 2H, J = 8.4 Hz), 7.46 (t, 2H, J = 7.8 Hz), 7.62 (m, IH), 7.88 (d, 2H, J = 7.1 Hz), 8.65 (s, IH), 9.14 (s, IH), 10.32 (s, IH). MS (DCI/NH₃) m/e 456 (M+NH4)⁺, 439 (M+H)⁺. Anal calcd for C₂₅H₃oN₂O₅».75 H₂O: C, 66.43; H, 7.02; N, 6.20. Found: C, 66.53; H, 6.79; N, 6.22. [α]_d = -12° (CH₃OH, c = .013 g/mL).

Example 34

Example 34A

The desired compound was prepared by adding 4-bromo-tert-butylbenzene to a 0 °C solution of nBuLi in diethyl ether . The resulting 4-tert-butylphenyllithium solution was added to a -78 °C solution of N-BOC-tBu(OH) tyrosine in diethyl ether. The solution was stirred at -78 °C for 30 minutes, warmed to 0° over 1 hour and quenched with an aqueous solution of NH4CI. The aqueous layer was extracted twice with diether ether and the combined organics were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Flash chromatography gave the BOC- protected compound which was immediately taken up in 4N HCl-dioxane and stirred for 30 minutes. The resulting slurry was diluted with diethyl ether, filtered and dried for 16 hours under high vacuum, to give 34a.

Example 34B

The desired compound was prepared according to the method of Examples 19C and 32E, except substituting 34a for 19b, and substituting succinate ester 1 for succinate ester 3. H NMR (300 MHz, CD₃OD) δ 0.67 (d, 3H, J = 6.5 Hz), 0.75 (d, 3H, J = 6.4 Hz), 0.95 (m, 3H), 1.16 (m, IH), 1.35 (s, 9H), 1.52 (m, IH), 1.82 (m, IH), 1.94 (m, IH), 2.34 (m, IH), 2.46 (m, IH), 2.81 (dd, IH, J = 6.2, 14.2 Hz), 3.1 1 (dd, IH, J = 4.7, 14.2 Hz), 4.89 (bds, IH), 4.94 (m, IH), 5.59 (m, IH), 5.73 (m, IH), 6.68 (d, 2H, J = 8.5 Hz), 7.11 (d, 2H, J = 8.4 Hz), 7.55 (d, 2H, J = 6.7 Hz), 7.97 (d, 2H, J = 6.8 Hz), 8.59 (d, IH, J = 5.6 Hz). MS (DCI/NH3) m/e 508 (M+H)⁺.

Example 35

The desired compound was prepared according to the method of Example IF, except substuting the compound of Example 34 for ie. 1H NMR (300 MHz, CD₃OD) δ 0.67 (d, 3H, J = 6.4 Hz), 0.74 (d, 3H, J = 6.4 Hz), 0.86 (m, 2H), 0.95 (m, IH), 1.14 (m, IH), 1.34 (s, 9H),

1.42 (m, IH), 1.77 (m, IH), 2.03 (m, IH), 2.43 (m, IH), 2.83 (dd, IH, J = 9.8, 13.9 Hz), 3.10 (dd, IH, J = 4.4, 13.9 Hz), 4.80 (m, IH), 4.92 (m, IH), 5.53 (m, IH), 5.77 (m, IH), 6.69 (d, 2H, J = 7.6 Hz), 7.13 (d, 2H, J = 8.5 Hz), 7.54 (d, 2H, J = 8.5 Hz), 7.97 (d, 2H, J = 7.6 Hz). ^I3C NMR (CD₃OD) δ 21.46, 24.45, 26.49, 30.55, 31.45, 32.29, 36.00, 37.37, 41.63, 47.08, 49.84, 56.31, 115.63, 116.28, 126.74, 129.24, 129.70, 131.31, 134.12, 138.71, 157.17, 158.54, 172.87, 176.02, 199.57. MS (DCI/NH₃) m/e 523 (M+H)⁺. Anal calcd for C₃₎H₄₂N₂O₅»0.5 H₂O: C, 70.03; H, 8.15; N, 5.27. Found: C, 69.92; H, 8.15; N, 5.21.

Example 36

Example 36A

A suspension of succinic anhydride (4 g, 40 mmol), allyl alcohol (2.7 mL, 40 mmol) and DMAP (5.9 g, 48 mmol) in 200 mL toluene was refluxed for 4 hours and then cooled to ambient temperature and concentrated. The residue waspartitioned between EtOAc and brine. The aqueous layer was extracted with EtOAc and then acidified to pH 2 with 6M HCl. The acidic aqueous phase was extracted with EtOAc (3x) to give an organic layer which was washed with brine (2x), dried (MgSO4), filtered and concentrated to afford 3_6_a (5.96 g) as a clear liquid which was used without further purification.

Example 36B

To a solution of carboxylic acid 36a (3 g, 19 mmol) in 95 mL CH2CI2 was added EDC

(1.8 g, 9.5 mmol). The reaction mixture was stirred for 3 hours and then poured into a separatory funnel containing 20 mL of ice water. The organic layer was washed with ice-cold water, saturated aqueous NaHCO₃ and brine, dried with MgSO4, filtered and concentrated in vacuo to afford 36b (2.8 g) which was used without purification.

Example 36C

To a solution of R-2-( -butyl)-succinic acid-4-t-butyl ester (1 g, 4.35 mmol), O- benzylphenylalanine hydrochloride salt (1.52 g, 5.22 mmol, Aldrich), HOBT (704 mg, 5.22 mmol) and NMM (1.4 mL, 13 mmol) in 22 mL DMF at 0 °C was added EDC (1 g, 5.22 mmol) in a single portion. The resulting solution was allowed to slowly warm to ambient temperature and then was stirred for 3 days. The reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were washed with IM NaHSO4, IM NaHCO₃ and brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified by flash cliromatography (CH2CI2 then 2% MeOH-CH2θ2) to give 36c (1.96 g) as a yellow oil.

Example 36D

Hydrogenation of benzyl ester 3^c (1.96 g, 4.2 mmol; 200 mg 10% Pd/C; methanol; 1 atm hydrogen) gave 36d (1.57 g) as a thick oil which was used without further purification.

To neat anhydride 36b (2.7 g, 9 mmol) was added a solution of carboxylic acid 36d (1.57 g, 4.16 mmol) in 10 mL CH2CI2, Et₃N (864 uL, 6.24 mmol) and DMAP (21 mg, 9 mmol). The resulting yellow solution was refluxed in an oil bath at 50 °C for 3 hours, cooled, concentrated and then stirred in the presence of 50 mL 5% NaHCO3 for 30 minutes. This mixture was diluted with EtOAc and the separated aqueous layer was extracted with EtOAc. The combined organic layers were washed with IM NaHSO4 and brine, dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatographed (15% ethyl acetate-hexane then 35% ethyl acetate hexane) to give 36e (952 mg) as a yellow foam.

Example 36E

The desired compound was prepared according to the method of Examples IE and F, except substituting 36e for Id. mp 126-129 °C. ^lH NMR (300 MHz, DMSO-d6) δ 0.6-1.0 (m, 8H), 1.1-1.4 (m, 2H), 1.8-2.2 (m, 2H), 2.6-3.2 (m, 6H), 4.2-4.6 (m, 3H), 5.2-5.4 (m, 2H), 5.8-6.0 (m, IH), 7.1-7.3 (m, 5H), 8.4-8.6 (m, IH), 8.45-8.55 (m, IH), 8.70 and 8.73 (two s, IH), 10.36 and 10.40 (two s, IH). MS (DCI/NH3) m/e 433 (M+H)+ 450 (M+NH4)+.

Example 37

To a solution of the compound of Example 36 (329 mg, 0.76 mmol) in 6 mL THF was added palladium(O) bis(dibenzylideneacetone) (44 mg, 0.08 mmol), triphenylphosphine (42 mg, 0.16 mmol) and morpholine (662 uL, 7.6 mmol). The resulting clear, yellow solution was stirred for lhour and then concentrated. The residue was partitioned between CH2CI2 and H2O and the separated aqueous layer was extracted with CH2CI2 (2x). The aqueous layer was concentrated, redissolved in H2O, filtered and the desired compound (135 mg) was isolated by reverse-phase HPLC (0-30% CH₃CN/H2O; 21mm Dynamax 60A C18 column; 12 mL/minutes). mp 120-121 °C. !H NMR (300 MHz, DMSO-d6) δ 0.60 (d, 3H, J = 5.4 Hz), 0.67 (d, 3H, J = 5.7 Hz), 0.8- 1.0 (m, 2H), 1.1-1.3 (m, IH), 1.91 (dd, IH, J = 14.4,7.8 Hz), 2.10 (dd, IH, J = 14.4, 6.6 Hz), 2.36 (t, 2H, J = 6.3 Hz), 2.6-2.9 (m, 5H), 2.70 (t, 4H, J = 4.8 Hz), 3.05 (dd, IH, J = 14.1, 4.2 Hz), 3.52 (t, 4H, J = 4.8 Hz), 4.4-4.5 (m, IH), 7.1-7.3 (m, 5H), 8.47 (d, IH, J = 8.4 Hz). MS (DCI/NH3) m/e 393 (M+H)⁺. Anal calcd for C2θH₂8N₂θ6»1.0 H₂O: C, 57.93; H, 7.90; N, 8.44. Found: C, 57.91; H, 7.55; N, 8.76. [α] = +62 ° (c 0.3, MeOH).

Example 38

The desired compound was prepared according to the method of Example 6 substituting succinate ester 4 for 5 and ketone 19b for 2c. ^lH NMR (300MHz, DMSO-dβ) d 9.18 (s, IH), 8.76 (s, IH), 8.5-8.4 (m, IH), 7.92-7.88 (d, 2H, J=7.1 Hz), 7.58-7.57 (m, IH), 7.48-7.45 (m, IH), 7.03-6.98 (m, 3H), 6.85-6.82 (d, 2H, J=7.4 Hz), 6.61-6.58 (d, 2H, J=8.2 Hz), 5.45-5.40 (m, IH), 3.10-2.87 (m, 2H), 2.8-2.6 (m, 3H), 2.23 (s, 3H), 1.88-.187 (m, IH), 1.2-1.15 (m, 2H). MS (ESI) m/e 487 (M-H)\ Anal. Calcd for: C₂9H 2N₂O5»0.75H2O: C, 69.37; H, 6.72; N, 5.57. Found: C, 69.37; H, 6.74; N, 5.88.

Example 39

The desired compound was prepared according to the method of Examples 10A,10B and 5 except substituting 27 for iOa and 9a for ic. *H NMR (300MHz, DMSO-dό) d 11.98 (s, IH), 10.63 (s, IH), 8.83 (s, IH), 8.41 (s, IH), 8.27-8.2 (m, IH), 8.01-7.98 (d, IH, J=9.5 Hz), 7.50-7.48 (m, IH), 7.27-7.18 (m, 2H), 6.98-6.85 (m, 3H), 6.76-6.74 (d, 2H, J=8.4 Hz), 5.27- 5.22 (d, IH, J=8.4 Hz), 5.18-5.15 (d, IH, J=9.6 Hz), 3.82-3.77 (t, IH, J=9.5, 7.7 Hz), 2.80- 2.75 (m, IH), 2.40-2.33 (m, IH), 2.25-2.21 (m, IH), 1.41-1.30 (m, IH), 1.25-1.20 (m, 3H), 1.00 (s, 9H). MS (ESI) m/e 480 (M+H)+, 478 (M-H)-. Anal. Calcd for: C27H N₃O₄«0.50H₂O: C, 66.37; H, 7.01; N, 8.68. Found: C, 66.39; H, 6.96; N, 8.45.

Example 40

The desired compound was prepared according to the method of Example 6 substituting succinate ester 4 for 5 and ketone 15a for 2c. H NMR (300MHz, DMSO-dβ) d 10.31 (s, IH), 8.61 (m, IH), 8.55-8.52 (d, IH, J=8.1 Hz), 7.94-7.91 (d, 2H, J=8.5 Hz), 7.58-7.55 (m, IH), 7.48-7.45 (m, 2H), 7.25-7.14 (m, 5H), 7.00-6.98 (d, 2H, J=7.8 Hz), 6.85-6.82 (d, 2H, J=7.9 Hz), 5.51-5.49 (m, IH), 3.14-3.08 (m, IH), 2.91-2.83 (m, IH), 2.71-2.59 (m, IH), 2.33-2.26 (m, 2H), 1.83-1.80 (m, 2H), 1.23-1.18 (m, 3H). MS (ESI) m/e 471 (M-H)-. Anal. Calcd for: C29H₃₂N₂O4«0.50H20: C, 72.32; H, 6.90; N, 5.81. Found: C, 72.57; H, 6.88; N, 5.80. Example 41

Example 41 A

The desired compounds was prepared according to the method of Example 27B, except substituting allyl bromide for cinnamyl bromide.

Example 41b

A solution of 41 a (5.0 g, 19.4 mmol) in THF (60 mL) at 0°C was treated with 9-BBN, stirred at ambient temperature for 1.5 hours, treated sequentially with DMF, [1,1 - bis(diphenylphosphino)-fenocene]dichloropalladium (790 mg, 0.97 mmol), 3,4,5- trimethoxybromobenzene (14.4 g, 58.3 mmol) and cesium carbonate (38.6 g, 118.5 mmol), stirred at 60°C for 5.5 hours, cooled to room temperature and diluted with water, extracted with ethyl acetate, and the combined organic layers were washed with water and brine, dried (Na2SO4) and concentrated to an oil. The oil was purified on silica gel with 10% to 30% ethyl acetate/hexane to provide 4.95 g (59.9%) of 41b as a yellow oil. MS (APCI) m/e 427 (M+H)+. Example 41C

The desired compound was prepared according to the method of Example27D and 27E, except substituting 41b_ for 27_£. MS (ESI) m/e 383 (M+H)⁺ .

Example 41 D

A solution of 41C (755 mg, 1.97 mmol) in DMF (15 mL) at 0 °C was treated sequentially with HOBT (294 mg, 2.17 mmol), NMM (477 mL, 438.8 mg, 4.35 mmol), EDC (417 mg, 2.17 mmol) and indoleketone-tert-leucine, iOa (500 mg, 2.17 mmol) , stirred at room temperature for 17 hours, and diluted with water, extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried (Na2SO4), and concentrated. The residue was purified on silica gel with 50% ethyl acetate/hexane to provide 402 mg (34%) of the title compound as a pale yellow foam. MS (APCI) m/e 595 (M+H)+.

Example 41 E

A solution of 41d (400 mg, 0.673 mmol) in trifluoroacetic acid (3 mL) was stirred at room temperature for 4 hours, and concentrated. The residue was purified on silica gel with 0.1% acetic acid in 10% MeOH/CH2Cl2 to provide 353.4 mg (94.7%) of title compound as a white solid. MS (ESI) m/e 555 (M+H)⁺.

Example 41F

A solution of 4Je. ( 26 mg, 0.588 mmol) in DMF (15 mL) at 0 °C was treated sequentially with HOBT (103.4 mg, 0.765 mmol), NMM (168 mL, 154.6 mg, 1.53 mmol), EDC (146.6 mg, 0.765 mmol) and O-(tert-butyldimethyl-silyl)hydroxyamine (112.6 mg, 0.765 mmol), stined at room temperature for 17 hours, and diluted with water, extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried (Na2SO4), and concentrated. The residue was purified on silica gel with 7% MeOH/CH2Cl2 to provide 32 mg (9.56%) of the title compound as a pale pink solid. IH NMR (300 MHz, DMSO-d₆) δ 0.979 (s, 9H), 1.130-2.000 (m, 4H), 2.272-2.392 (m, 2H), 2.700 (m, IH), 3.546 (s, 3H), 3.568 (s, 6H), 3.783 (t, IH), 5.146 (d, IH), 5.255 (d, IH), 6.282 (s, 2H), 7.138-7.237 (m, 2H), 7.457 (d, IH), 7.909 (d, IH), 8.182 (d, IH), 8.412 (s, IH), 8.849 (s, IH), 10.633 (s, IH), 11.969 (s, IH). MS (APCI) m/e 570 (M+H)⁺. High resolution MS (FAB) m/e calcd for (M+H)+ : C₃oH₄oN₃O₈: 570.2815. Found : 570.2822.

Example 42

The desired compound was prepared according to the methods of Example 41, except substituting 2c for 10a in Example 41D. IH NMR (300 MHz, DMSO-d₆) δ 1.236-1.377 (m, 4H), 2.274- 2.441 (m, 2H), 2.918-2.988 (dd, IH), 3.111-3.183 (dd, IH), 3.570 (s, 3H), 3.638 (s, 6H), 3.826 (t, IH), 5.222 (d, IH), 5.387 (q, IH), 6.343 (s, 2H), 7.118-7.276 (m, 9H), 7.439 (d, IH), 8.125 (d, IH), 8.297 (s, IH), 8.435 (d, IH). MS (APCI) m/e 604 (M+H)⁺. Anal, calcd for C₃₃H₃₇N₃O₈-HOAc: C, 63.33; H, 6.22; N, 6.33. Found: C, 63.10; H, 6.05; N, 6.05.

Example 43

Example 43A

A solution of Boc-tert-leucine-N-methoxyl-N'-methylamide (1.15 g, 4.2 mmol) in ethyl ether (70 mL) at -78°C was treated with 2-lithioanisole (prepared by addition of 2-bromoanisole (1.57 mL, 2.36 g, 12.6 mmol) to a solution of n-butyllithium (2.5M/hexane, 5.04 mL, 12.6 mmol) in ethyl ether (15 mL) at 0°C), stined at -30°C to -45°C for 1 hour and poured onto 1:1 Et2θ: 0. IM HCl. The aqueous layer was separated, and extracted with ether, the combined organic layers were washed with brine, dried (Na2SO4), and concentrated. The residue was purified on sihca gel with 2%-5%-10% ethyl acetate/hexane to provide 788 mg (58%) of the title compound as a colorless oil. MS (DCI/NH₃) m/e 322 (M+H)+.

Example 43B

A solution of 43a (786 mg, 2.45 mmol) in HCl/dioxane (4M, 6 mL) was stirred at room temperature for 1 hour, diluted with ether, filtered. The filtrate was washed with ether, and dried under high vacuum to provide 550.6 mg (87.3%) of the title compound as a white sohd. MS (APCI) m/e 222 (M-HC1+H)+.

Example 43C

The desired compound was prepared according to the method of Examples 41D-F, except substituting ketone 43b for 10a. IH NMR (300 MHz, DMSO-d₆) δ 0.883 (s, 9H), 1.171-1.399 (m, 4H), 2.291-2.515 (m, 2H), 2.728-2.833 (m, IH), 3.575 (s, 3H), 3.635 (s, 6H), 3.797 (s, 3H),3.772-3.813 (m, IH), 5.199 (d, IH), 5.304 (d, IH), 6.388 (s, 2H), 6.960-7.009 (t, IH), 7.104 (d, IH), 7.449-7.501 (t, IH), 7.550-7.588 (dd, IH), 7.929 (d, IH), 8.852 (s, IH), 10.645 (s, IH). MS (ESI) m/e 561 (M+H)⁺. Anal, calcd for C29H40N2O9: C, 62.12; H, 7.19; N, 4.99. Found: C, 62.20; H, 7.22; N, 4.71.

Example 44

Example 44A

The desired compound was prepared following the methods of Examples 43 A and 43B, except substituting 3-lithioanisole for 2-lithio anisole. MS (ESI) m/e 222 (M-HC1+H)⁺. Example 44B

The desired compound was prepared following the methods of Example 43C, except substituting 44a for 43a. IH NMR (300 MHz, DMSO-d₆) δ 0.933 (s, 9H), 1.138-1.328 (m, 4H), 2.244-2.428 (m, 2H), 2.794-2.826 ( , IH), 3.584 (s, 3H), 3.666 (s, 6H), 3.793 (s, 3H),3.774-3.812 (m, IH), 5.223 (d, IH), 5.298 (d, IH), 6.339 (s, 2H), 7.151-7.187 (dd, IH), 7.388-7.441 (m, 2H), 7.571 (d, IH), 8.137 (d, IH), 8.859 (s, IH), 10.655 (s, IH). MS (ESI) m/e 561 (M+H)+. Anal, calcd for C29H40N2O9O.25H2O: C, 61.63; H, 7.22; N, 4.95. Found: C, 61.78; H, 7.48; N, 4.58.

The desired compound was prepared according to the method of Example 2C, except coupling succinate 7 instead of 4 with ketone 2c. MS (ESI) m/e 461 (M + H)⁺.

Example 45B

The desired compound was prepared according to the method of Example 4 IB, except using 45_a instead of 41a.

Example 45C

The desired compound was prepared according to the method of Examples IE and 5A-B except substituting 45_b_ from above for 1<± mp 104 °C. ²H NMR (300 MHz, DMSO-dό) 11-92 (s, IH), 10.35 (d, IH, J=0.7 Hz), 8.70 (d, IH, J=1.4 Hz), 8.47 (d, IH, J=8.5 Hz), 8.36 (d, IH, J=3.0 Hz), 8.18-8.14 (m, IH), 7.47-7.42 (m, IH), 7.32-7.11 (m, 7H), 6.33 (s, 2H), 5.41- 5.31 (m, IH), 3.63 (s, 6H), 3.56 (s, 3H), 3.16-3.07 (m, IH), 2.98-2.88 (m, IH), 2.77-2.65 (m, IH), 2.77-2.65 (m, 3H), 1.93-1.87 (m, IH), 1.44-1.18 (m, 4H). MS (ESI) m/e 588 (M + H)+.

Example 46

The desired compound was prepared according to the method of Example 45A-45C, except substituting ketone 9a for 2c in Example 45A. mp 126 °C.lH NMR (300 MHz, DMSO-d6) 11-96 (d, IH, J=2.2 Hz), 10.37 (d, IH, J=1.4 Hz), 8.69 (d, IH, J=1.5 Hz), 8.39 (d, IH, J=2.9 Hz), 8.18 (d, IH, J=7.4 Hz), 8.05 (d, IH, J=9.2 Hz), 7.48-7.43 (m, IH), 7.24-7.13 ( , 2H), 6.32 (s, 2H), 5.09 (d, IH, J=8.8 Hz), 3.60 (s, 6H), 3.56 (s, 3H), 2.96-2.87 (m, IH), 2.47-2.27 (m, 2H), 2.22-1.98 (m, 2H), 1.47-1.24 (m, 4H), 0.97 (s, 9H).¹ C NMR (300 MHz, DMSO-d₆) 193.9, 174.0, 152.5, 137.7, 136.6, 135.4, 134.4, 125.5, 122.9, 121.7, 121.4, 116.9, 112.1, 105.3,60.3,59.9,41.0,35.3,34.2,31.5,28.2,27.1. MS (APCI) m/e 554 (M + H)+.

Example 47A

The desired compound was prepared according to the method of Example 43A and 43B, except using phenyl lithium in place of 3-lithioanisole.

The desired compound was prepared according to the method of Example 45A-45C, except substituting ketone 47a for 2c in Example 45A. mp 146 °C. IH NMR (300 MHz, DMSO-d₆) 10.36 (s, IH), 8.67 (s, IH), 8.22 (d, IH, J=8.0 Hz), 7.97-7.92 (m, 2H), 7.63-7.45 (m, 3H), 6.38 (s, 2H), 5.27 (d, IH, J=8.1 Hz), 3.68 (s, 6H), 3.59 (s, 3H), 2.98-2.87 (m, IH), 2.46-2.26 (m, 2H), 2.22-1.96 (m, 2H), 1.44-1.30 (m, 4H), 0.92 (s, 9H).^J3C NMR (300 MHz, DMSO-d₆) 200.3, 174.4 , 167.6, 164.8, 152.6, 138.2, 137.8, 135.4, 133.0, 128.6, 128.0, 105.3, 59.9, 59.5, 55.7, 40.6, 35.3, 35.2, 34.0, 31.6, 28.0, 26.9.

Example 48

The desired compound was prepared according to the method of Example 2C and 2D, except coupling succinate 9 instead or 4 with ketone 9a instead of 2c. *H NMR (300 MHz, DMSO-d₆) 11.93 (s, IH), 10.48 (d, IH, J=1.7 Hz), 8.74 (d, IH, J=1.7 Hz), 8.42 (d, IH, J=3.1 Hz), 8.16 (t, 2H, J=8.1 Hz), 7.47-7.43 (m, IH), 7.23-7.1 1 (m, 2H), 7.23-7.11 (m, 2H), 6.28 (s, 2H), 5.76-5.56 (m, IH), 5.14 (d, IH, J=8.5 Hz), 4.96-4.90 (m, 2H), 3.58 (s, 6H), 3.56 (s, 3H), 2.80-2.70 (m, IH), 2.46-2.33 (m, IH), 2.33-2.13 (m, 3H), 2.10-1.98 (m, IH), 1.38-1.18 (m, 4H), 1.00 (s, 9H). MS (ESI) m/e 594 (M + H)+- Anal. Calcd for: C₃₃ H43 N₃ O₇.0.50H₂O: C, 65.76; H, 7.35; N, 6.97. Found: C, 65.70; H, 7.46; N, 6.98.

The desired compound was prepared according to the method of Example 2C and 2D, except coupling succinate IQ instead of 4 with ketone 9a instead of 2£.

^JH NMR (DMSO-d6) δ 0.93 (s, 9H), 1.0-1.43 (m, 6H), 1.95-2.02 (m, IH), 2.10-2.21 (m, IH), 2.78-2.90 (m, IH), 3.21 (t, 2H, J=9 Hz), 4.34 (s, 2H), 7.28 (d, IH, J=9 Hz), 7.21-7.36 (m, 5H), 7.44-7.50 (m, 2H), 7.53-7.62 (m, IH), 7.94 (d, 2H, J=8 Hz), 8.24 (d, IH, J=9 Hz), 8.68 (s, IH), 10.38 (s, IH). MS (DCI/NH3) m/e 469 (M+H)+. Anal, calcd for: C27H36N2O5: C, 69.20; H, 7.74; N, 5.99. Found: C, 69.35; H, 7.70; N, 6.02.

Example 50A

The desired compound was prepared according to the methods of Examples 18A and B. except substituting N-Boc-alpha-cyclohexyl alanine for N-Boc-phenylalanine.

Example 50B

The desired compound was prepared according to the method of Example 2C and 2D, except coupling succinate JO instead or 4 with ketone 50a instead of 2c. *H NMR (300 MHz, DMSO-d6) δ 0.78-1.0 (m, 2H), 1.03-1.68 (m, 16H), 1.78-1.90 (m, IH), 1.91-2.13 (m, 2H), 2.60-2,74 ( , IH), 3.21-3.29 (m, 2H), 4.4 (s, 2H), 5.20-5.37 (m, IH), 7.20-7.39 (m, 5H), 7.41-7.52 (m, 2H), 7.55-7.63 (m, IH), 7.90 (d, 2H, J=8 Hz), 8.38 (d, IH, J=8 Hz), 8.70 (s, IH), 10.38 (s, IH); MS (DCI/NH3) m/e 509 (M+H)+. Anal, calcd for: C30H40N2O5: C, 70.83; H, 7.92; N, 5.50. Found: C, 70.63; H, 8.13; N, 5.63.

Example 51 A

11 5JLa

The desired compound was prepared according to the method of Example 2C except substituting succinate ester ϋ for 4 and ketone 9_a for 2c. ^lU NMR (300 MHz, DMSO-dό) δ 8.39 (s, IH), 8.21 (d, IH), 8.06 (d, IH), 7.47 (d, IH), 7.24- 7.18 (m, 2H), 5.10 (d, IH), 2.89-.287 (m, IH), 2.69 )t, IH), 2.45 (dd, IH), 2.29 (dd, IH), 2.07-1.91 (m, 2H), 1.58-1.42 (m, 2H), 1.37 )s, 9H), 0.97 (s, 9H). MS (DCI/NH₃) m/e 439 (M+l)⁺.

Example 5 IB

51a 51b

A solution of the alkyne 51a (211 mg, 0.48 mmol) and l-bromo-3,4,5-trimethoxybenzene (131 mg, 0.528 mmol) in 2:1 triethylamine/acetonitrile (4.8 mL) was degassed with N2 for 20 minutes, treated with 10% palladium on activated carbon (20 mg, 0.0192 mmol) and copper iodide (5 mg, 0.024 mmol), heated at reflux for 24 hours, cooled to 23 °C, filtered through Celite, and concentrated to a residue. The residue was purified on sihca gel with 50% ethyl acetate/hexane to provided 130 mg of 5_lb as a white solid. ^!H NMR (300 MHz, DMSO-d₆) δ 8.41 (s, IH), 8.22 (d, IH), 8.08 (d, IH), 7.47 (d, IH), 7.22-7.18 (m, 2H), 6.63 (s, 2H), 5.14 (d, 1Η), 3.73 (s, 6H), 3.63 (s, 3H), 2.96-.290 (m, IH), 2.37-2.10 (m, 4H), 1.65-1.55 (m, 2H), 1.38 (s, 9H), 0.98 (s, 9H). MS (DCI/NH3) m/e 605 (M+l)⁺.

Example 51c

5JLJ2 5_i£

A solution of the alkyne 5_lb_ (1 15 mg, 0.19 mmol) in 1 : 1 methanol/ethyl acetate (4 mL) was treated with 10% palladium on activated carbon (20 mg, 0.019 mmol) under an atmosphere of hydrogen (H2 balloon) for 16 hours, filtered through Celite, and concentrated to provide 115 mg of 5Jc. ^!H NMR (300 MHz, DMSO-d₆) δ 8.35 (s, IH), 8.24 (d, IH), 8.11 (d, IH), 7.48 (d, IH), 7.24-7.14 (m, 2H), 6.29 (s, 2H), 5.12 (d, IH), 3.69 (s, 6H), 3.57 (s, 3H), 2.82-2.81 (m, IH), 2.42 (dd, IH), 2.20 (dd, IH), 2.13 (t, IH), 1.37 (s, 9H), 1.33-1.24 (m, 6H), 0.98 (s. 9H). MS (ESI) m/e 607 (M-l)+.

Example 5 ID

The ester 51c was convereted to the des compound following the procedures described in Examples IE, 5A and 5B. ^JH NMR (300 MHz, DMSO-d6) δ 8.68 (s, IH), 8.36 (d, IH), 8.24 (d, IH), 8.07 (d, IH), 7.48 (d, IH), 7.24-7.14 (m, 2H), 6.29 (s, 2H), 5.10 (d, IH), 3.69 (s, 6H), 3.57 (s, 3H), 2.82 (m, IH), 2.21-1.98 (m, 4H), 1.40-1.18 (m, 6H), 0.99 (s, 9H). MS (DCI/NH₃) m/e 568 (M+l)+.

Anal, calcd for C₃iH4iN₃O7»H₂O: C, 63.57; H, 7.40; N, 7.17. Found: C, 63.52; H, 7.15; N, 6.67.

Example 52

The desired compound was prepared according to the method of Example 27B, except substituting 1,3-dibromo-l-propene for cinnamyl bromide.

Example 52B

A solution of Example 52_a (3.0 g, 8.9 mmol) in DMF (100 mL) at room temperature was treated with [l,l'-bis(diphenylphosphino)-feπocene] dichloropalladium (363 mg, 0.445 mmol), 3- acetimidobenzenoboronic acid (2.39 g, 13.35 mmol) and cesium carbonate (8.7 g, 26.7 mmol), stirred at 60°C for 7 hours, cooled to room temperature and diluted with water, extracted with ethyl acetate, and the combined organic layers were washed with water and brine, dried (Na2SO4) and concentrated to an oil. The oil was purified on silica gel with 50% ethyl acetate/hexane to provide 716.9 mg (20%) of 52b as a yellow oil. MS (ESI) m/e 392 (M+H)⁺.

Example 52C

The olefin 52b was converted to the desired compound 52c following the procedure of

Example 5 IC .

The desired compound was prepared according to the methods of Example 41C-F, except substituting 52c for 4ib. IH NMR (DMSO-d6) δ 0.989 (s, 9H), 1.23-1.39 (m, 4H), 1.98 (s, 3H), 2.19-2.36 (m, 2H), 2.72-2.76 (m, IH), 3.77-3.83 (t, IH, J=8.1 Hz), 5.12-5.16 (d, IH, J=6 Hz), 5.26-5.29 (d, IH, J=7.5 Hz), 6.37-6.39 (d, IH, J=7.8 Hz), 6.72-6.77 (t, IH, J=7.8 Hz), 7.16-7.25 (m, 4H), 7.45-7.48 (IH), 7.94-7.97 (d, IH, J=9.6 Hz), 8.21-8.24 (IH), 8.38 (s, IH), 8.80 (s, IH), 9.71 (s, IH), 10.6 (s, IH), 11.94 (s, IH). MS (ESI) 537 (M+H)+, 559 (M+Na)⁺.

Example 53

The desired compound was prepare according to the od of Example 52B-D except substituting 3-methoxybenzenoboronic acid for 3-acetimidobenzenoboronic acid. IH NMR (DMSO-d6) δ 0.99 (s, 9H), 1.22-1.27 (m, 4H), 2.27-2.39 (m, 2H), 2.74 (dt, IH), 3.59 (s, 3H), 3.76-3.81(t, IH, J=8.4 Hz), 5.13-5.16 (d, IH, J=9.6 Hz), 5.25-5.27 (d, IH, J=7.2 Hz), 6.31- 6.33 (d, IH, J=7.2 Hz), 6.55-6.68 (2H), 6.75-6.81 (t, IH, J=7.8 Hz), 7.18-7.23 (m, 2H), 7.45- 7.48 (d, IH, J=8.7 Hz), 7.94-7.98 (d, IH, J=9.3 Hz), 8.21-8.24 (d, IH, J=9.6 Hz), 8.40 (s, IH), 8.84 (s, IH), 10.63 (s, IH), 11.97 (s, IH). MS (ESI) 510(M+H )+, 532 (M+Na)+.

Example 54

Example 54A

41d 54a

A solution of 41d (249 mg, 0.419 mmol) in dichloromethane (5 mL) at room temperature was treated with methanesulfonyl chloride (144.2 mg, 97.4 ml, 1.26 mmol), and triethylamine (127 mg, 175 ml, 1.26 mmol), stiιτed for 6 hours, and quenched with water, extracted with dichloromethane, dried (Na2SO4) and concentrated . The residue was purified on silica gel with 40% to 60% ethyl acetate/hexane to provide 239.4 mg (85%) of 5_4a as a white foam. MS (ESI) m/e 673 (M+H)+.

Example 54B

A solution of 54a (237 mg, 0.353 mmol) in THF (4.5 mL) at 0°C was treated with IN HCl (4.5 mL), stirred at room temperature for 17 hours, and concentrated. The residue was extracted with dichloromethane, dried (Na2SO4), and concentrated. The residue was purified on silica gel with 0.1% acetic acid in 10% MeOH/CH2Cl2 to provide 177 mg (79%) of 5_4b as a white solid. MS (ESI) m/e 631 (M-H)-. Example 54C

The desired compound was prepared according to the method of Examples 5A-B, except substituting 5.4b. for 4. IH NMR (DMSO-d6) δ 1.004 (s, 9H), 1.247-1.347 (m, 4H), 2.269- 2.418 (m, 2H), 2.800-2.833 (m, IH), 3.554 (s, 3H), 3.593 (s, 6H), 3.649 (s, 3H) , 3.768-3.822 (IH), 5.100-5.127 (d, IH, J=8.1 Hz), 5.232-5.256 (d, IH, J=7.2 Hz), 6.301 (s, 2H), 7.403- 7.464 (m, 2H), 7.874-7.900 (d, IH, J=7.8 Hz), 8.136-8.165 (d, IH, J=8.7 Hz), 8.215-8.240 (d, IH, J=7.5 Hz), 8.634 (s, IH), 8.855 (s, IH), 10.652 (s, IH). MS (ESI) 648 (M+H)+, 665 (M+NH4)+.

Claims

WE CLAIM

1 . A compound of formula

or pharmaceutically acceptable salt, ester or prodrug thereof wherein

W is NHOH or -OH;

R¹ and R⁴ are independently selected at each occunence from hydrogen or alkyl of one to four carbon atoms;

V is O or NOR¹;

R² is selected from the group consisting of (a) hydrogen, (b) hydroxy,

(c) alkoxy of one to six carbon atoms,

(d) alkyl of one to six carbon atoms,

(e) alkyl of one to six carbon atoms substituted with (1) halogen, (2) hydroxy,

(3) alkoxy of one to six carbon atoms,

(4) cycloalkyl of three to eight carbon atoms,

(5) alkanoyloxy wherein the alkyl portion is of one to four carbon atoms,

(6) pyridyl, (7) pyridyl substituted with alkyl of one to four carbon atoms, (8) phenoxy wherein the phenyl ring is unsubstituted or substitued with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

-CO2R⁷ wherein R⁷ is hydrogen or alkyl of one to four carbon atoms, -COJ R ⁷R⁸ wherein R⁷ is defined above and R⁸ is selected from hydrogen, alkanoyl of one to four carbon atoms, alkyl of one to four carbon atoms, phenyl, and phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

-CONR⁹R¹⁰ wherein R⁹ and R¹⁰ are independently selected from hydrogen and alkyl of one to four carbon atoms, and -CO2R⁹, and

(10) -S(O)_nRⁿ wherein n is 0, 1 or 2 and R¹¹ is selected from (a) alkyl of one to six carbon atoms,

(b) phenyl,

(c) phenyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO₂R⁷,

-CONR⁷R8,

(d) thienyl,

(e) thienyl substituted with alkyl of one to four carbon atoms,

(f) phenylalkyl wherein the alkyl portion is of one to four carbon atoms, (g) phenylalkyl wherein the alkyl portion is of one to four carbon atoms, and the phenyl ring is substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO2R⁷, and -CONR⁷R⁸,

(h) thienylalkyl wherein the alkyl portion is of one to four carbon atoms, and (i) thienylalkyl wherein the alkyl portion is of one to four carbon atoms and the thienyl ring is substituted with alkyl of one to four carbon atoms, and 85 (11) -NR¹²R¹³ wherein R¹² is hydrogen or alkyl of one to four carbon atoms and

R¹³ is selected from

(a) hydrogen,

(b) alkyl of one to four carbon atoms,

(c) -CO2R¹⁴ wherein R¹⁴ is independently selected at each occunence from 90 alkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, phenyl, phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, 95 alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, nitro, cyano, 00 cyanoalkyl,

-SO2NH2, -CO2R⁷, and -CONR⁷R⁸, phenylalkyl wherein the alkylene portion is of one to four carbon 105 atoms, phenylalkyl wherein the alkylene portion is of one to four carbon atoms, and the phenyl ring i<- substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, 10 alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, 115 -SO2NH2,

-CO2R⁷, and -CONR⁷R⁸, heteroarylalkyl wherein the alkylene portion is of one to four carbon atoms, and the heteroaryl group is selected from 120 furyl, pyridyl, thienyl, benzimidazolyl, imidazolyl, 125 thiazolyl, and benzothiazolyl wherein the heteroaryl group is unsubstituted or substituted with alkyl of one to four carbon atoms, and (d) -SO₂R¹⁴, 130 or R¹² and R¹³, together with the N atoms to which they are attached define a heterocycle selected from morpholinyl, thiomorpholinyl, thiomorpholinyl sulfone, 135 pynolidinyl, piperazinyl, piperidinyl, succinimidyl, maleimidyl, 140 glutarimidyl, phthalimidyl,

I NΓÇö

H₃C' ^ O o

H ^Ha^SC^C-^N ' -

145

(f) alkenyl of two to six carbon atoms,

(g) alkenyl of two to six carbon atoms substituted with (1) halogen,

155 (2) hydroxy,

(3) alkoxy of one to six carbon atoms,

(4) cycloalkyl of three to eight carbon atoms,

(5) alkanoyloxy wherein the alkyl portion is of one to four carbon atoms,

(6) pyridyl,

160 (7) pyridyl substituted with alkyl of one to four carbon atoms, (8) phenoxy wherein the phenyl ring is unsubstituted or substitued with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy,

165 alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

170 -CO₂R⁷, -CONR⁷R⁸, phenyl, and phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms,

175 hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano,

180 cyanoalkyl,

-CO₂R⁹, and

-CONR⁹R!0,

(10) -S(O)_nRⁿ and

185 (11) -N ╬¬2R13;

R³ is selected from the group consisting of

(a) alkyl of one to ten carbon atoms,

(b) alkenyl of two to ten carbon atoms, 90 (c) cycloalkyl of three to eight carbon atoms,

(d) (cycloalkyl)alkyl wherein the cycloalkyl portion is of three to eight carbon atoms, and the alkylene portion is of one to six carbon atoms,

(e) cycloalkylene of five to eight carbon atoms,

(f) (cycloalkylene)alkyl wherein the cycloalkylene portion is of three to eight carbon 95 atoms, and the alklene portion is of one to six carbon atoms,

(g) phenyl wherein the phenyl ring is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, 00 halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO₂R⁷, 05 -CO₂NR⁷R⁸, phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, 10 halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO₂R⁹, and 15 -CONR⁹R¹⁰, (h) phenylalkyl wherein the alkylene portion is of one to six carbon atoms, and the phenyl ring is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, 20 alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, 25 -CO2R⁷,

-CO2NR⁷R⁸, alkoxyalkyloxy, phenyl, and phenyl substituted with 1, 2, or 3 substutuents independently selected from 30 alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, 35 cyanoalkyl,

-CO2R⁷ and -CO2NR⁷R⁸,

(i) -(CH2)m-T-(CH2)n-R¹⁵ wherein m and n are independently 0, 1 , 2, 3 or 4, T is O or S, and 40 R¹⁵ is selected from the group consisting of alkyl of one to four carbon atoms, phenyl, and phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, 45 hydroxy, alkoxy of one to four carbon atoms, alkoxyalkyloxy halogen, haloalkyl of one to four carbon atoms, 50 cyano, cyanoalkyl, -CO R⁷, and -CONR⁷R⁸, phenyl, and 55 phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, 60 halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl, -CO₂R⁷, 65 -CONR⁷R⁸, and

(j) fluorenylalkyl wherein the alkylene portion is of one to four carbon atoms. R⁵ is selected from the group consisting of (a) alkyl of one to six carbon atoms, 270 (b) alkyl of one to six carbon atoms substituted with cycloalkyl of three to eight carbon atoms, hydroxy, alkoxy, -SR⁷, 275 -NR⁷R⁸,

-CO₂R⁷, -CONR⁷R⁸, guanidyl, phenyl, 280 phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, 285 haloalkyl of one to four carbon atoms, nitro, cyano, cyanoalkyl, carboxyalkyloxy, 290 -S(O)_nR¹⁶ wherein n is 0, 1 or 2 and R¹⁶ is alkyl of one to four carbon atoms, -SO₂NH₂, -CO2R⁷, and -CONR⁷R⁸, and 295 phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, and 300 haloalkyl of one to four carbon atoms, naphthyl, naphthyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, 305 alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, indolyl, indolyl substituted with 310 alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, 315 -SO₂R¹³,

-SO₂NH₂, -CO2R⁷ and -CONR⁷R⁸, pyridyl, 320 pyridyl substituted with alkyl of one to four carbon atoms, pyrazolyl, pyrazolyl substituted with alkyl of one to four carbon atoms, 5-oxadiazolyl, imidazolyl, and 325 imidazolyl substituted with alkyl of one to four carbon atoms,

(c) phenyl and

(d) phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, 330 alkoxy of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms; R⁶ is selected from the group consisting of (a) alkyl of one to six carbon atoms,

(c) phenyl, (d) phenyl substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, cyano,

-NR⁷R⁸,

-SO₂NR⁷R⁸, -SO₂R¹⁶,

-CH2NR¹⁸R¹⁹, wherein R¹⁸ and R¹⁹ are independently selected at each occunence from hydrogen and alkyl of one to four carbon atoms, or R¹⁸ and R¹⁹ together with the N atom to which they are attached define a a 5-or 6-membered heterocyclic ring selected from (1) morpholinyl,

(2) thiomorpholinyl,

(3) thiompholinyl sulfone,

(4) py╧Çolidinyl,

(5) piperazinyl, (6) 3-ketopiperazinyl and

(7) piperidinyl, -CONR⁷R⁸, -CO2R⁷, and phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents 70 selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, (e) 1,3-benzodioxole, 75 (f) indolyl,

(g) indolyl substituted with alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, 80 alkoxy of one to four carbon atoms,

-SO₂NR⁷R⁸, -CO2R⁷, and phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from 85 alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms, (h) pynolyl, 90 (i) pynolyl substituted with alkyl of one to four carbon atom

(j) imidazolyl,

(k) imidazolyl substituted with alkyl of one to four carbon atoms, 00 benzimidazolyl,

(m) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from 95 alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (f)-(m) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of 00 alkyl of one to six carbon atoms

-CONR R⁸, -SO₂NR⁷R⁸ and -SO₂R¹⁴, (n) pyridyl, 05 (o) pyridyl substituted with alkyl of one to four carbon atoms, (p) thienyl,

(q) thienyl substituted with halogen, alkyl of one to four carbon atoms, and 410 haloalkyl of one to four carbon atoms,

(r) thiazolyl, (s) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and 415 haloalkyl of one to four carbon atoms,

(t) oxazolyl, (u) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and 420 haloalkyl of one to four carbon atoms,

(v) furyl, (w) furyl substituted with halogen, alkyl of one to four carbon atoms, and 425 haloalkyl of one to four carbon atoms,

(x) benzofuryl, (y) benzofuryl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and 430 haloalkyl of one to four carbon atoms,

(z) benzothiazolyl, and (aa) benzothiazolyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and 435 haloalkyl of one to four carbon atoms.

2. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined in claim 1 wherein R⁶ is selected from the group consisting of

(a) alkyl of one to six carbon atoms, and

(b) alkyl of one to six carbon atoms substituted with hydroxy, alkoxy, halogen, and

-CO2R¹⁷ wherein R¹⁷ is selected from hydrogen, alkyl of one to four carbon atoms and alkenyl of two to four carbon atoms.

3. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined in claim 1 wherein R⁶ is selected from the group consisting of

(c) phenyl,

(d) phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, cyano,

-NR⁷R⁸,

-SO₂NR⁷R⁸,

-SO₂R¹⁶, -CH2NR¹⁸R¹⁹, wherein R¹⁸ and R¹⁹ are independently selected at each occunence from hydrogen and alkyl of one to four carbon atoms, or R¹⁸ and R¹⁹ together with the N atom to which they are attached define a a 5-or 6-membered heterocychc ring selected from (1) morpholinyl, (2) thiomorpholinyl,

(3) thiomphotinyl sulfone,

(4) pynolidinyl,

(5) piperazinyl,

(6) 3-ketopiperazinyl and (7) piperidinyl, -CONR⁷R⁸, -CO2R⁷, and phenyl, wherein the phenyl ring may be substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, and

(e) 1,3-benzodioxole.

4. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined in claim 1 wherein R⁶ is selected from the group consisting of

(f) indolyl,

(g) indolyl substituted with alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, -SO NR⁷R⁸, -CO₂R⁷, and phenyl, wherein the phenyl ring may be substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms, (h) pynolyl,

(i) pynolyl substituted with alkyl of one to four carbon atom (j) imidazolyl, (k) imidazolyl substituted with alkyl of one to four carbon atoms,

G) benzimidazolyl,

(m) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (f)-(m) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms -CONR⁷R⁸, -SO2NR⁷R⁸ and

-SO₂R¹⁴, (n) pyridyl,

(o) pyridyl substituted with alkyl of one to four carbon atoms, (p) thienyl, (q) thienyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (r) thiazolyl, (s) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (t) oxazolyl, (u) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (v) furyl, (w) furyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (x) benzofuryl, (y) benzofuryl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms, (z) benzothiazolyl, and (aa) benzothiazolyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, and haloalkyl of one to four carbon atoms.

5. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined in claim 1 wherein

R¹ and R⁴ are hydrogen;

R² is selected from the group consisting of

(a) hydrogen,

(b) hydroxy,

(c) alkoxy of one to six carbon atoms,

(d) alkyl of one to six carbon atoms, (e) alkyl of one to six carbon atoms substituted with

(2) -S^nR¹¹ wherein n is 0, 1 or 2 and R¹¹ is selected from (a) phenyl, (b) phenyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

-CO₂R⁷,

-CONR⁷R⁸, (c) thienyl and

(d) thienyl substituted with alkyl of one to four carbon atoms and

(3) -NR¹²R¹³ wherein R¹² and R¹³ are independently selected from hydrogen and alkyl of one to four carbon atoms and or R¹² and R¹³, together with the N atoms to which they are attached define a heterocycle of formula

(f) alkenyl of two to six carbon atoms; R³ is selected from the group consisting of (a) alkyl of one to ten carbon atoms,

(b) cycloalkyl of three to eight carbon atoms, and

(c) phenylalkyl wherein the alkylene portion is of one to six carbon atoms, and the phenyl ring is unsubstituted or substituted with 1 , 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

-CO₂R⁷, -CO₂NR⁷R⁸, phenyl, and phenyl substituted with 1, 2, or 3 substutuents independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, cyano, cyanoalkyl,

-CO R⁷ and -CO₂NR⁷R⁸; and

R⁵ is selected from the group consisting of (a) alkyl of one to six carbon atoms,

(b) alkyl of one to six carbon atoms substituted with cycloalkyl of three to eight carbon atoms, -CO₂R⁷, -SR⁷, phenyl, and phenyl substituted with 1, 2, or 3 substituents independently selected from alkyl of one to four carbon atoms, hydroxy, alkoxy of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, nitro, cyano, cyanoalkyl, -S(O)_nR¹⁶ wherein n is 0, 1 or 2 and R¹⁶ is alkyl of one to four carbon atoms,

-SO₂NH₂,

-CO2R⁷, and

-CONR⁷R⁸.

6. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined by claim 5 wherein W is NHOH and V is O.

7. A compound pharmaceutically acceptable salt, ester or prodrug thereof as defined in claim 6 wherein

R² is selected from the group consisting of hydrogen, hydroxy, alkenyl of two to six carbon atoms;

R³ is selected from the group consisting of isobutyl, cyclohexyl,

3-phenylpropyl,

3-(4-tolyl)propyl, biphenyloxy,

4-(phenylmethoxy)butyl, 4-(3,4,5-trimethoxyphenyl)butyl, and

3-(3,4,5-rrimethoxyphenyl)propyl;

R⁵ is selected from the group consisting of (a) alkyl of one to six carbon atoms, (b) alkyl of one to six carbon atoms substituted with cycloalkyl of three to eight carbon atoms, carboxy, phenyl, and hydroxyphenyl.

8. A compound or pharmaceutically acceptable salt, ester or prodrug thereof as defined by claim 7 wherein

R⁶ is selected from the group consisting of (a) alkyl of one to six carbon atoms, (b) alkyl of one to six carbon atoms substituted with -CO2R¹⁷,

(c) phenyl,

(d) phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms,

-NR⁷R⁸, cyano,

-SO₂NR⁷R⁸,

-SO₂R¹⁶, -CH₂NR¹⁸R¹⁹, -CONR⁷R⁸ and -CO2R⁷,

(e) indolyl,

(g) pynolyl,

(h) pyrrolyl substituted with alkyl of one to four carbon atoms, (i) benzimidazolyl, (j) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (e)-(j) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms, -SO₂R¹⁴, -CONR⁷R⁸ and -SO₂NR⁷R⁸,

(k) thienyl,

(m) thiazolyl,

(n) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms,

(o) oxazolyl and

9. A compound or pharmaceutically acceptable salt, ester or prodrug thereof as defined by claim 8 wherein

R⁶ is selected from the group consisting of (a) phenyl, (b) phenyl substituted with 1 , 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, -NR⁷R⁸, cyano, -SO₂NR⁷R⁸, -SO₂R¹⁶,

-CH₂NRl⁸R¹⁹, -CONR⁷R⁸ and -CO₂R⁷, (c) indolyl, (d) indolyl substituted with alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and phenyl, wherein the phenyl ring may be substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, haloalkyl of one to four carbon atoms, and alkoxy of one to four carbon atoms,

(e) pyrrolyl,

(f) pyrrolyl substituted with alkyl of one to four carbon atoms, (g) benzimidazolyl,

(h) benzimidazolyl substituted with 1, 2 or 3 substituents independently selected from alkyl of one to four carbon atoms, halogen and haloalkyl of one to four carbon atoms, provided that in (c)-(h) above, when the heterocycle is attached at a carbon atom, the N atom may bear a substituent selected from the group consisting of alkyl of one to six carbon atoms,

-SO₂R¹⁴, -CONR⁷R⁸ and -SO NR⁷R⁸, (i) thienyl, (j) thienyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (k) thiazolyl, G) thiazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms, (m) oxazolyl and (n) oxazolyl substituted with halogen, alkyl of one to four carbon atoms, and haloalkyl of one to four carbon atoms.

10. A compound or pharmaceutically acceptable salt, ester or prodrug thereof as defined by claim 9 wherein

R⁶ is selected from the group consisting of

(a) phenyl and

(b) phenyl substituted with 1, 2, or 3 substituents selected from alkyl of one to four carbon atoms, halogen, hydroxy, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkoxy of one to four carbon atoms,

-NR⁷R⁸, cyano,

-SO₂NR⁷R⁸,

-SO₂R¹⁶,

-CH₂NRl⁸R¹⁹,

-CONR⁷R⁸, and

-CO₂R⁷.

11. A compound or pharmaceutically acceptable salt, ester or prodrug thereof as defined by claim 1 selected from the group consisting of

12. A method for inhibiting matrix metalloproteinases in a mammal in need of such treatment, comprising adrriinistering to the mammal a therapeutically effective amount of a compound of Claim 1.

13. A composition for inhibiting matrix metalloproteinases comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of Claim 1.